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I 
SOCIAL AND ECONOMIC IMPLICATIONS 
OF CANCER IN THE UNITED STATES 
Dorothy P. Rice, Director, and Thomas A. Hodgson, Ph.D., Division of Arialysis 
INTRODUCTION 
Death rates reported to the World Health 
Organization by member countries reveal that, 
for most countries in North America, Europe, 
and Oceania, cancer is the second leading cause 
of death.1 Of all 1971 deaths among 27 selected 
countries, the proportion that was classified as 
malignant neopIasms ranged from 13 to 24 per-
cent, with a median of 19 percent. For the lead­
ing cause of death, heart disease, the proportion 
ranged from 20 to 40 percent, with a median of 
31 percent.2 Standardized death rates for cancer 
in 1972 at age 45 years and over ranged from 
411 to 843 per 100,000 males and from 313 to 
601 per 100,000 females, with a general level of 
cancer mortality in these countries of 600 per 
100,000 and 450 per 100,000 for males and fe­
males, respectively.1 
Cancer usually strikes those who are middle-
aged and over. But even in the less developed 
countries of Africa, South and Middle America, 
and Asia, where the proportion of the popula­
tion surviving to late adult life is lower and ec­
onomic development has not progressed as far as 
in the developed nations, cancer may be the 
fifth or sixth leading cause of death.1 Of all 
1971 deaths in 11 selected Third World coun­
tries, the median proportion that was due to 
malignant neoplasms was 11 percent, compared 
with the 13.5 -percent median for heart disease.3 
It is estimated that over 1 million persons 
will have been diagnosed as having cancer in 
1977 in the United States (including 300,000 
new cases of nonmelanoma skin cancer) and that 
385,000 Persons will die of the disease.A The
. 
social and economic implications of cancer for 
victims and the society at Iarge are pain, suffer­
ing, disability, and death; millions of years of 
life lost; vast amounts of human and economic 
resources devoted to detection, diagnosis, and 
treatnient; and billions of dollars of economic 
output forgone annually because of lost human 
resources. Goals in the fight against cancer, and 
other diseases as well, are prevention before the 
disease strikes, cure with minimum untoward ef­
fects when it occurs, and maximum quality of 
life if cure is not possible. Faced with limited re-
sources and a multiplicity of diseases and other 
social problems demanding attention, it is essen­
tial to know and understand the magnitude of 
the economic and social costs of cancer and 
their relationship to the total burden on society. 
Social Costs and Quality of Life 
While. it has long been recognized that there 
are certain noneconomic effects of illness and 
disease, such as pain and suffering, in recent 
years there has been increased interest in this as­
pect of disease cost. Social costs refer to psycho-
social deteriorations that are brought about by 
disease.6 Persons exposed to social costs include 
cancer victims and their famifies, victims’ friends 
and coworkers, and care givers. They number 
several million persons in the United States.5 
Recent research has revealed the influence of 
mortality on the family and its life cycle.6>T 
Mortality has direct consequences for the fam­
ily, affecting, for example, duration of marriage 
1
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and age at widowhood: In the long run, Iarge re­
ductions in mortality can influence behavioral 
patterns. Studies of economic costs are, to a 
large extent, refinements of an accepted meth­
odology, but measures and methodology for 
social costs remain to be developed. 
Cancer, esflecially advanced cancer, may 
bring about personal catastrophes that are not 
reflected in the direct and indirect economic 
costs of cancer that have been estimated to this 
date. A cancer victim may suffer loss of a body 
part, impaired speech, disfigurement, disability, 
impending death, pain, and grief. The victim, 
and those around him or her, may be forced into 
economic dependence rind social isolation, un­
wanted job changes, loss of opportunities for 
promotion and education, relocation of living 
quarters, and other undesired changes in life 
plans. The environment created by cancer in­
duces anxiety, reduced self-esteem and feelings 
of well-being, resentment, and emotional prob­
lems that often require psychotherapy. Mental 
illness may develop, leading to family conflict, 
antisocial behavior, and suicide. The cancer vic­
tim and others may experience marked personal­
ity changes and reduced sexual function. Dis­
rupted developmcpt and delinqtiency may occur 
among children. Cancer frequently reduces the 
qua.lky of life beyond the restorative capability 
of current rehabilitation efforts. “The combina­
tion of financial strain and psychosocial prob­
lems is especially devastating. 
These social costs have been documented in 
numerous studies and appear to be widespread. 
Cancer Care, Inc. and the National Cancer 
Foundation, Inc. found that most families with 
a member suffering from advanced cancer 
needed help to maintain family stability. Two-
thirds of the families studied reported emotional 
or adjustment problems on the part of family 
members, and one-third underwent changes in 
life plans such as disrupted employment.g Can­
cer treatment has been found to cause a finan­
cial burden that creates anxiety for the families 
of pediatric cancer patients.9 Half of 70 families 
surveyed reported that expenses, including 
nonmedical costs, plus pay lost as a result of the 
child’s disease, amounted to more than one- . 
fourth of the weekly family income. Fortu­
nately, quality of life for cancer patients is an 
important issue and considerable attention i: 
ing given to it.1 0-13 
Although quantifying social costs h:,s be 
rather intractable process, some progress 
been made. Qualitative social costs hitve 1 
translated into money costs by using ma 
values or shadow prices= of imputed costs. It 
been estimated that social costs vary quite : 
by form of cancer and may greatly excetd d 
and indirect economic costs if the social co: 
death is included. Excluding the cost of d 
produces a money value for social costs tha 
sembles direct economic costs of cancer.g~b 
though these estimates need refinement, 
point out the importance of social cost: anc 
misallocation of resources that may occur w 
only economic costs are considered. 
Increased effort is needed to refine 
methodology and develop the necessary L 
Frequently, there is little observable d ffer~ 
in the effectiveness of alternative treatment, 
cancer (simple versus radical mastectc myj 
example), at least in terms of survival and re 
rence rates. In these circumstances it VJOUI 
especially helpful to quantify and compare 
quality of Iife under alternative treatmc nts. 
ferent alternatives involve tradeoffs bet weer 
creased probability df survival, length of s 
val, and reduced quality of life. If quali ;y-oi 
data could be integrated with survival prob: 
ties, then the optimal treatment al ierm 
could be determined.14 
Indicators must be developed and data 
Iected to estimate quality of life and social ci 
The state of the art js still rather primitive, b 
‘Shadow prices are accounting prices at tachc 
goods and services for which there arc no mar <et p. 
The shadow prices are the costs incurred in obtainin 
items in question. 
b~e minimum snnual social costs of cance. 
estimated to be about $2.5 billion, excluding txtin( 
costs, and about $138 billion if costs of exti lctio 
included. The dollar magnitudes of these cost!; hav 
doubtedly increased since this research5 was pub] 
in 1975. Abt’s estimates include the social cost 
curred by victims, spouses, children, parent:, sib 
friends, coworkers, and care givers resulting from e: 
tion,, and mental illness, family conflict, ant socia 
havior, sexual loss, grief, limited consciousness, sek 
tion, isolation, and discrimination associated with ca 
2 
has begun to attract attention.1 5-20 Measures of 
the impact of sickness on a person in terms o 
his or her sense of well-being, as weIl as eyalu4 -
tions of well-being of family members and ass”b­
ciates, are required. For cancer, indicators must 
reflect the reduced self-esteem, emotionaI prob­
lems, pain, and suffering caused by disfigure­
ment, disability, social isolation, economic de­
pendence, and impending death–in short, th~ 
tics (Health Interview Survey) and the Health 
Care Financing Administration (Current Medi­
. care Survey), cancer registries, and .~atient self­
,?	 help group:; such as Lost Chord Clubs (laryngec­
tomy patients), Reach to Recovery (mastectomy 
patients), and Ostomy Clubs, represent possible 
vehicles for collecting information on quality of 
life	 and social costs. 
The Commission on Cancer of the American 
cancer. 
Although direct measures of social costs and 
quality of life are not available, and considerable 
methodological research and data collection are ~ 
necessary if social costs are to be adequately 
quantified, the situation is not completely hope-
less. Different scales have been developed to as­
sess the rehabilitation of patients by measuring 
functional status. The Performance Status Scale 
assesses mobility and ability to carry out usual 
roles. More comprehensive measures of func- I 
tional status axe the Pulses Functional Profile , 
and the Barthel Index.21 Pain and suffering can 
be measured by duration and seventy of pain, as 
indicated by the potency of drugs needed fod re-
Iief. Suicide, mental ilIness, or psychiatric e 
can indicate grief, worry, and emotional stt ssj 
These can be shadow priced by the costs of 
arudgesic drugs and psychotherapy. Dollar values 
have also been estimated, albeit crudely, “for 
other social costs,14 including disrupted child 
development and sexual limitations. If quality of 
# life can be quantified in money terms, then the 
quality of life, quantity of life, and direct and 
indirect economic costs can be expressed in 
terms of a common denominator and can then 
be compared and combined to obtain the total 
cost of cancer. 
Initial efforts at measuring perceptions of 
the quality of life are encouraging.16Y22-26 Also 
of interest is the Sickness Impact Profile, which 
attempts to measure behavioral expressions of 
sickness .2° Construction of quality-of-life indi­
cators requires surveys of affected individuals, 
and the task will not be easy. Questions on qual­
ity of life will be difficult to answer and involve 
painful and emotional topics. The surveys will 
have to be very carefully constructed. National 
household interview surveys, such as those con­
ducted by the National Center for Health Statis-j 
reduced quality of life that often accompanies ~ 
$	
College of Surgeons has recognized the need for 
data quality of Iife. Since January 1973, theon 
commission has required that each hospitaI can­
cer registry evaluate patients’ performance status 
in order for the hospital to gain approval by the 
American College of Surgeons} 2 As a result, the 
Department of Clinical Statistics at Memorial 
Hospital for Cancer and Allied Diseases in New 
York requires information on quality of life 
from all cancer. patients. Each year, respondents 
provide information on employment, functional 
capabilities, and whether, after treatment, the y 
have realized their employability potential and 
resumed normal family and community func­
tions. Such surveys, already producing valuable 
information, might be expanded to obtain addi­
tional data on the patient and to begin ascertain­
~ing cancer’s imp-act” on others ‘besides the 
iDatient.l 2
* 
Despite these efforts, estimation of social 
costs remains a task for the future. The remain­
der of this paper focuses on economic costs: Re-
cent estimates of economic costs, as well as 
some methodologiczd aspects, are discussed, and 
new information on certain costs by cancer 
site is provided. 
Economic Costs 
Cancer, like other diseases, produces eco­
nomic as well as social costs. Direct economic 
costs are those connected with prevention, diag­
nosis, and treatment. These include expenditures 
for hospital and nursing home care, physicians’ 
and nurses’ services, drugs, medical research, 
medical personnel training, facility construction, 
and other expenditures, such as those for public 
health education. Indirect costs are the losses in 
output, such as time lost from work because of 
mortality, morbidity, and disability. Economic 
costs represent forgone alternatives: Direct costs 
3 
... 
are the value of resources that could be allocated 
to other uses in the absence of disease, and in-
direct costs are the value of idle resources and 
lost output .27 
In the next section, 1975 economic costs of 
neoplasms and their relationship to total costs 
for all illnesses are discussed, and the economic 
assumptions and principles used to calculate in-
direct costs are summarized. The section follow­
ing presents costs of short-term hospital care, 
physicians’ services, and mortality by cancer 
site. The last section provides a summary and 
conclusion; the appendix contains an explana­
tion of methodology. 
ECONOMIC COSTS IN 1975 
The most recent national estimates of dis­
ease costs in the United States are for fiscal 
year 1975.28 These calculations folIow closely, 
with some modifications, the methodology pio­
neered by Ricezg more than a decade ago and 
recently updated by Cooper and Rice.so In 
1975, the total estimated cost of illness ranged 
from $239 billion to $323 billion, depending on 
the discount rate employed, with neoplasms 
(benign and malignant) accounting for $19 
billion to $28 billion, or 8 to 9 percent of 
total costs. Neoplasms constitute one of the 
most costly disease categories, surpassed only 
by diseases of the circulatory system (18 to 19 
percent of total costs), and by accidents, poison­
ings, and violence (12 to 18 percent of total 
costs). Costs of neoplasms are similar in magni­
tude to those for mental disorders and diseases 
of the respiratory and digestive systems. 
Direct Costs 
Direct costs of neoplasms totaled $5.3 bil­
lion in fiscal 1975, representing 5.3 percent of 
the total dwect, expenditures for medical care 
(table 1). Hospital care expenditures of $4.1 bil­
lion accounted for more than 78 percent of the 
total direct costs of neoplasms, and an estimated 
$671 million, almost 13 percent of the total, 
was spent on physicians’ services. The remaining 
9 percent of direct expenditures was incurred 
for other professional services, drugs and drug 
sundries, and nursing home care. Thus by far the 
Dentists’ 
sarvices7.5% 
Hc4t@l 
:Sra4a.” 
ALL DISEASES 
HOWIUI 
.*ra 7.9. 
NEOPLASMS 
Figure 1. Percent distribution of direct expenditure I for 
easas and neoplasms, by type of expenditure: United 
fiscal year 1975 
largest share of expenses connected with 
prevention, diagnosis, and treatment of 
plasms is that incurred for hospital care (f 
1). This is quite different from the dis].rib~ 
of direct costs for all diseases combined. ? 
the amount spent on hospital care fo. al 
eases is the largest component of direct co. 
accounts for only about 47 percent of the 
expenditures, and significantly larger prt 
tions were spent on other types of care f( 
diseases than for neoplasms. As shown ii 
appendix, however; the figure for physic 
services for neopksms ($671 million) is a se 
underestimate of expenditures. 
Indirect Costs 
The value of current and future ou cpu 
because of reduction or cessation of prodt 
activity due to morbidity and mortality is F 
4 
direct cost of cancer. Cancer prevents people 
from leading their accustomed productive lives 
in terms of working and keeping house. They 
may lose time from their activities, be forced 
out of their jobs, or become institutionalized. 
Persons dying of cancer in a given year would 
otherwise be expected to live into the future 
with an estimated life expectancy. The calcula­
tion of the loss of output resulting from mortal­
ity and morbidity involves the application of 
several economic assumptions and principles, 
which are summarized as follows: 
Earnings.-The appropriate measure of out-
put loss for individuals is earnings, and the 
proper measure of expected earnings is the 
arithmetic average or mean. In this report, out-
put losses are based on annual mean earnings by 
age and sex provided by the Bureau of Labor 
Statistics,zs adjusted for wage supplements such 
as employer contributions for social insurance, 
private pensions, and welfare funds. 
Cross-sectional profiles of mean earnings by 
age and sex are used to estimate lifetime earn-
in~. In applying these data, it is assumed that 
the ihture pattern of earnings for an average 
individual within a sex group will follow the pat-
tern repoi-ted by the Bureau of Labor Statistics 
during the base year 1975. This model recog­
nizes that the average individual may expect his 
or her earnings to rise with age and experience in 
accordance with the cross-sectional data for 
1975. 
The use of average earnings based on cross-
sectional surveys would understate the present 
value of expected lifetime earnings if future ec­
onomic growth patterns were not taken into ac­
count. Therefore an average annual rate of gain 
in productivity is projected and applied as a par­
tial offset to the discount rate. 
The discount mte.-The calculation of the 
present wdue of expected lifetime earnings 
raises questions about the importance of dis­
counting and choosing the appropriate discount 
rate. From the economist’s viewpoint, the ar­
ithmetic sum of lifetime earnings overstates the 
present value of an individual. Determining the 
present value of the future earnings stream is the 
correct way to me’asure economic value over a 
period of time; discounting converts a stream of 
earnings into its present wdue. 
Economists agree that comparison of 
streams of earnings over varying timespans 
should employ the process of discounting, but 
there is no agreement on the discount rate to be 
used.s1~3z The higher the discount rate, the 
lower the present value of a given money stream. 
With a high discount rate, earnings far into the 
future yield a relatively small present value. 
Conversely, lowering the discount rate increases 
the present value of future earnings. 
Two basic concepts underlie the choice of a 
discount rate: opportunity cost concept and 
subjective time preference. Opportunisty cost re­
fers to the notion that resources should be val­
ued according to what they could earn in alter-
native uses, assuming that the alternative uses 
are productive and resources so used today will 
generate a larger or more highly valued output 
in the future. The rate of return on corporate 
earnings and the government borrowing rate 
have been suggested as two measures of the dis­
count rate. Time preference refers to the usual 
preference for a dollar now compared with a 
dollar in the future, a preference that cannot be 
measured directly. 
The discount rate should be the result of a 
balance between opportunity cost and time 
preference. How to arrive at this balance is not 
specified, however, and the usual practice is to 
present a number of alternative rates. The 6-
percent and 10-percent rates in this report pro-
vide a range that encompasses the rates generaIly 
in use today for costs of disease. It is usually, if 
not always, assumed that a singIe discount rate 
applies to all subgroups of a population. There is 
evidence, however, that discount rates vary sig­
nificantly with age, income, sex, and race.33 
Mortality also varies according to these factors, 
Wd the effect on costs of assuming a uniform 
discount rate is not known. A uniform rate is a 
simplification required by limitations of data. 
The discount rate can be adjusted for ex­
pected changes in productivity. An annual in-
crease in productivity of 2 percent, for example, 
can be incorporated into the discounting calcu­
lations to obtain a net effective discount rate. 
Thus a 6-percent discount rate adjusted for an 
annual 2-percent rise in productivity will yield 
an effective discount rate of approximately 4 
percent (1.06/1 .02 = 1.039). A 10-percent 
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D discount rate similarly adjusted results in a rate 
of 8 percent (1 .10/1 .02 = 1.078). The present 
values of lifetime earnings by age and sex for 
discount rates of 6 and 10 percent, adjusted for 
an annual increase in productivity of 2 percent a 
year, are given in tabIe 2 and figure 2. 
Employment. –The estimate of lifetime ear­
ningstakes into account varying work-experience 
rates. The assumption is that an individual will 
be working and productive during his or her ex­
pected lifetime in accordance with the current 
pattern of work-experience for his or her sex 
and age group. For this calculation, work­
expenence rates for 1975 published by the Bu­
reau of Labor Statistics were used.zs Unfortu­
nately, 1975 was a year of high unemployment. 
With less than full employment, the estimated 
cost of illness is lower than it would be under 
full employment because Iosses due to illness 
cannot be isolated from Iosses due to unemploy­
ment. To overcome this downward bias in the 
estimate of illness costs, work-experience rates 
during a year of full employment should be 
used. 
Household work. –Marketplace earnings un­
derestimate the loss resulting from women’s ill­
nesses, and the value of household work must be 
added to earnings. Based on a time-motion study 
of housewives,s4 the relevant market wages for 
various services performed were mtdtiplied by 
the time required for doing that service to ob­
tain an estimate of the cost of replacing the 
housewife’s duties with person-hours from the 
labor force. This takes into account the house-
wife’s age, number of children, and age of 
youngest child. The value of household work 
was imputed for all women ever married until 
age 65, and beyond age 65 for women with 
spouses present or who were female heads of 
household. It was also imputed for married men 
with spouses present. Imputed household values 
plus marketplace earnings give total earnings, 
which were used to compute the present wdue 
of lifetime earnings .2s 
Consumption.–In the past, it has been ques­
tioned whether the cost of morbidity and mor­
tality due to illness is an individual’s output or 
an individual’s output minus his or her con­
sumption. 35-37 The concern of this report is 
with the cost of illness to society. The individ­
ual, not just the output he or she contribut~ 
excess of consumption, is valued by soci 
Economists today generally agree that ct~nsu 
tion should not be deducted? B 
Life expectancy. –Lifetime eamin 3s 1 
were calculated using modified genera ,:ion 
tables. These tables incorporate the assump 
that life expectancy changes between the y 
1975 and 2050, with each cohort having a 
ferent mortality experience.zs 
Value of human life. –One, if not the c~ 
issue with respect to indirect costs is how 
value life. The method in this report is cded 
human capital approach because an emplo 
person is seen as producing a stream of out 
over the years that is valued at the individt 
earnings. The main criticism of this mctho[ 
ogy is that it excludes intangibles, only cot 
earnings, and undervalues some groups rela 
to others because earnings may not accura 
reflect one’s ability to produce. Thus men 
more higldy valued than women, white per, 
more than black persons, and middle-aged F 
ple more than the young and elderly, wth F 
of the difference due to racial and sexual 
crimination. 
An alternative approach favored by ;om{ 
called the willingness-to~ay method, which . 
ues human life according to the amount peo 
are willing to spend to obtain reduction: in 
probability of death. Objections to this metl 
are that the value of individual lives deptmds 
the income distribution, with the rich ~ble 
pay more than the poor, and that it is cxce 
ingly &ffiCult for perSonS to place a Value 
small reductions in the probability of deal h. C 
of the few attempts to apply willingness.to-I 
was in a study of heart and circulate 
disease 39 
Unfortunately, the precise nature of the 
lationship between values calculated by .he i 
man capital approach and those implied by i 
willingness-to-pay method has not been det 
mined. Although it not known to what extc 
the two values would differ if willingness to F 
for small reductions in mortality risk cc,uld 
calculated, lifetime earnings as estimated by i 
human capital method may at least be z. 10V 
bound to a person’s willingness to pay fcr a I 
creased risk of death.40~41 In this regard it is 
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teresting to note that several estimates of the 
value of avoiding increased risk of death do not 
differ greatly fr~m the largest of the present val­
ues of lifetime earnings in table 2.42 This com­
parison is tentative, however, since the popula­
tion bases are not the same in each case, and the 
human capital values are age specific while the 
willingness-to-pay estimates are not. The human 
capital approach is still most often used. It pro­
vides valuable information based on reliable sta­
tistics, so long ~ one realizes its limitations. 
Findings 
Number of deaths, person-years lost, and 
lost earnings in 1975 for all diseases and neo­
plasms by age and sex axe shown in table 3. 
Twenty percent more males than females died of 
neoplasms, compared with 24 percent more for 
all diseases. But owing to the longer life expect­
ancy among women, totaI person-years lost was 
about the same for each sex. Men, however, ac­
counted for a much larger share of lost earnings 
due to lower labor force participation rates 
among women, lower earnings for women who 
do work, and still lower values imputed for 
women who keep house. For all diseases, mortal­
ity costs for males (71 percent) were signifi­
cantly higher than for females (29 percent) (fig­
ure 3). For neoplasms, the difference was less; 
mortality costs for males comprised 59 percent 
of the total. This difference in mortality costs 
by sex is mostly due to a difference in age at 
death for females dying of neoplasms and fe­
males dying of all diseases. Forty-three percent 
of women whose deaths were caused by neo-
ALL DISEASES NEOPLASMS 
Figure 3. Percent distribution of indirect mortality costs et 
6-percent discount rate for all diseases and neoplasms, by 
sex: Unitad Stetes, fiscal year 1975 
plasms were in the under-65-years age group, 
most productive years, while the correspon 
figure for all diseases is only 28 percent. 
Estimates of the total indirect costs of 
plasms and all diseases are given in table ~ 
much larger proportion of indirect costs was 
to mortality for neoplasms than for all disc z 
94 percent versus 60 percent, at a 6-percent 
count rate (figure 4). Morbidity accounted 
only a small proportion of the indirect cost 
neoplasms (6 percent). This disparity bet w 
neoplasms and all diseases in the distribution 
indirect costs results directly from a similar 
parity in person-years lost due to morbidity 
mortality. For neoplasms, only 2 percent ,> 
person-years lost resulted from morbidity, w 
14 percent,of person-years lost was due to i 
hidity for all diseases. That neoplasms cau. 
relatively greater burden from mortality c 
pared with morbidity than do all diseases c 
bined is further evidenced by the fo110win3 
tistics: Neoplasms account for 16 percen 
person-years lost due to mortality from a!l 
eases but only 2 percent of person-years lost 
to morbidity. Also, data from the Divisi!]l 
Vital Statistics of the National Center for He 
Statistics show that, while malignant neopk 
account for 18 percent of all deaths, only 1 
cent of all persons with limitations of acti 
report malignant neoplasms as the cause. 
Morbidity costs for the currently emplc 
and those unable to work each accounted 
about 40 percent of morbidity losses for 
plasms as well as for all diseases, with the 
maining one-fifth split between females kee! 
ALL DISEASES NEOPLASMS 
Figure 4. Percent distribution of indirect costs at 6-pert en 
count rate for all disaases and neoplasms, by type >f 
United Statas, fiscal year 1975 
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house and the institutionalized population. A 
final point to note is that, while a change in the 
discount rate produces a change in the amount 
of mortality costs and the relative contribution 
of mortality and morbidity to total costs, it 
produces almost no change in the proportion of 
mortality costs attributed to men and women. 
The dollar amounts and percent distribution 
of total economic costs in fi3cal year 1975 are 
given in table 5 by type of cost for all diseases 
and neoplasms. The total cost of neoplasms was 
almost $19 billion or over $22 billion in fiscal 
year 1975 depending on whether mortality costs 
are discounted at 6 percent or 10 percent. The 
indirect cost of mortzdity was by far the largest 
component of economic costs of neoplasms, 
accounting for 71 percent of the total at a 6-
percent discount rate. Morbidity contributed a 
very small share, only 5 percent, and direct costs 
made up 24 percent of the total (figure 5). In 
contrast, for all diseases, mortality contributed 
Oirect 
Mortdlsv 40.5% 
35.9% 
Morbldky 
. 
23.6% 
ALL DISEASES 
OirectMortality 23.6%
71.6% 
Marbidity 
4.9% 
NEOPLASMS 
Figure 5. Pertent distribution of economic costs at 6.parcent 
discount rate for all diseases and neoplasms, by type of 
COIR United States, f iscal year 1975 
only 36 percent, morbidity accounted for 24 
percent, and direct costs were 40 percent of the 
total at a 6-percent discount rate. 
Table 5 shows the significant impact of the 
discount rate on costs. The lower the discount 
rate, the higher the present value of future earn­
ings lost due to mortality. Although ordy the in-
direct cost of mortality is affected by changes in 
the discount rate, the resulting change in mor­
tality cost is large and produces significant shifts 
in the proportional distribution of costs. 
Neoplasms were responsible for about 9 per-
cent of the total costs of all diseases in fiscal 
year 1975. Direct costs of neoplasms were about 
5 percent of all direct costs, and morbidity due 
to neoplasms contributed nearly 2 percent of all 
costs associated with morbidity. However, neo­
pksms represented a much larger share of costs 
associated with mortality-between 18 and 20 
percent. 
ECONOMIC COSTS OF CANCER 
BY SITE 
Cancer is not a single disease, but a group of 
“diseases. A common characteristic is the uncon­
trolled growth of abnormal cells, but there are 
great differences hong various forms of cancer. 
Causes, appearance, and behavior are dissimi-
1=.43 su~iv~ rate5 show considerable ~~ation 
according to organ of origin. Cancers of the pan­
creas are highly fatal, with 5-yezu survival rates 
of only 1 percent. The 5-year survival rate for 
breast cancer, on the other hand, is around 65 
percent.A Trends in age-adjusted death rates also 
vary for different sites. In the United States, age-
adjusted death rates for malignant neoplasms of 
the respiratory system have increased dramat­
ically, rising from 21.6 per 100,000 white males 
and 4.6 per 100,000 white females in 1950 to 
54.6 deaths per 100,000 white males and 13.8 
per 100,000 white females in 1975. During this 
same period, age-adjusted death rates for can­
cers of the digestive organs and peritoneum de-
creased from 54.0 per 100,000 to 40.2 per 
100,000 white males and from 41.1 per 100,000 
to 26.4 per 100,000 white females .44 Expendi­
tures for resources in the form of hospital care 
and physicians’ services for prevention, diag­
nosis, and treatment of cancer, and the number 
9 
.. .	 of person-years and value of output lost due to 
premature mortality also vary significantly 
among cancer sites. . . 
For these reasons it is important to distin­
guish among cancer sites, and in this section es­
. .. timates of 1975 expenditures by cancer site for 
. . 
., short-stay hospital care and physicians’ services, 
.“ and indirect costs of mortality are presented.. . 
“. .“. Together these three categories account for 90 
. . . . + percent of the total economic costs of neo­.,.,. plasms. The two largest of the remaining cost 
., categories, those arisirig from morbidity and 
. . nursing home care, account for 5 to 7 percent of 
total costs, but cannot be estimated by cancer 
site. 
.’, 
Short-Term Hos~ital Care
. 
. -,. 
,. 
.“ 
,>. ” 
. . . 
. 
. . 
./ 
Table 6 presents the distribution of days of 
care for patients discharged from short-stay hos­
pitals in 1975 according to cancer site, age, and 
sex. Patients with neoplasms spent more than 
25.5 million days in short-stay hospitals in 1975. 
About 56 percent of these days (14.3 million) 
were used by persons under age 65, and 58 per-
cent (14.9 million) were used by females. Eighty-
three percent of days for benign neoplasms were 
used by those under age 65, and 78 percent, by 
females. For malignant neoplasms, the older age 
group accounted for slightly more days than 
those under age 65, while ut~lzation by females 
exceeded that by maIes by about 7.5 percentage 
points. 
More days of care were used by persons over 
age 65 for malignant neoplasms of the stomach, 
intestine and rectum, other digestive organs, 
male genital organs, and urinary organs. Younger 
persons accounted for more days of care for 
malignant neoplasms of the buccal cavity and 
pharynx, skin, breast, female genital organs, leu­
kemia and other lymphatic and hematopoietic 
tissues, and benign neopIasms. Days of care for 
patients with cancers of the trachea, lung, and 
bronchus, and of other and unspecified sites 
were ahnost evenly distributed by age. For pa­
tients under age 65, 71 percent of hospital days 
were for malignant neoplasms, while for those 
age 65 and over the figure is 93 percent. About 
one-third of days used by the younger patients 
were for malignant neoplasms of the intestine 
and rectum, respiratory organs, breast, and lym­
phatic and hematopoietic tissues, while t} 
sites plus male genitrd organs accounted fol 
most 50 percent of the days reported for 
tients age 65 and over. 
Excludlng neoplasms of the breast and g 
tal systems, males accounted for more of 
days resuhing from cancer of the buccal ca’ 
and pharynx, stomach, respiratory system, 
nary organs, and leukemia. Females usl:d m 
days of care for other digestive organs, o’ 
Iymphatic and hematopoietic tissues, and ber 
neoplasms, whiIe there was little difference 
utilization between the sexes for cancers of 
intestine and rectumY skin, and other and 
specified sites. 
Expenditures for short-stay hospital care 
shown in table 7. (See the appendix for an 
pkmation of the methodology that resulted ! 
significantly higher estimate than that made 
Georgetown University for short-term hosp 
care.zs ) The total spent for all neopl isms 
1975 was estimated at $4.1 billion, with 78 I 
cent, or $3.2 billion, spent for malignant L 
plasms. Average daily charges for hospital c 
vary according to the site of the,neoplasm : 
are somewhat higher for patients under age 
Nevertheless, the primary determinant of 
distribution of expenditures among sites and 
tween the two age groups and sexes is the m 
ber of days of care. Expenditures follow C1O: 
the distribution of days of care, and the cc 
ments reIating to hospital days also apply 
expenditures. 
Physicians’ Services 
Costs of physicians’ services in 1975 for 
neoplasms are estimated at more than $1.2 
lion as shown in table 8. (See the apper dix 
an explanation of the methodology that resul 
in significantly higher estimates than tho:,e m: 
by Georgetown University.28) Fifty-four I 
cent of this total ($672 million) was fcm in 
tient hospital surgery. The remainder was alm 
equally divided between inpatient hospitul m~ 
cal care ($274 million) and office aINi ot 
visits ($299 million). This pattern of exper 
tures did not prevail among all cancer sitts, h{ 
ever. Although surgery accounted for o~er i 
the expenditures for most sites, surgery F 
duced only 23 percent of the total costs for I 
10 
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kemia. At the other extreme, 77 percent of the 
total costs for cancers of female genital organs 
was surgery connected. Relatively small amounts 
were spent for medical care in the hospital for 
some sites, such as cancers of the skin (5 percent 
of the total), female genital organs (12 percent), 
and benign neoplasms (12 percent), while 41 
percent of the total spent for leukemia and al­
most one-third of expenditures each for diges­
tive and respiratory organs were for medical care 
in the hospital. With respect to amounts spent 
for office and other types of visits, cancers of 
the female genital, digestive, and respiratory or­
gans required relatively small expenditures (ap­
proximately 11 to 13 percent of their totals), 
while for benign neoplasms, leukemia, and skin 
cancers, 32, 36, and 42 percent of expenditures, 
i 
, 
,. 
respectively, were for office and other visits. 
Benign neoplasms accounted for nearly 55 
percent of the amount spent for all neoplasms 
for office and other visits, 22 percent of the cost 
of medical care in the hospital, and 43 percent 
of the total for surgery. Except for the residuaI 
category of “all other malignant neoplasms, ” in-
patient hospitzd medical care for cancer of the 
digestive system, and benign neophisms, no 
other site accounted for as much as 10 percent 
of expenditures when viewed according to type 
of visit. Further, there is no discernible pattern 
of expenditures by site according to type of 
visit. 
Mortality 
Tables 9 and 10 present data on deaths from 
neoplasms in 1975 by age, sex, ~ancer site, and 
color. Of almost 371,000 deaths, males ac­
counted for 54 percent, and females, 46 percent 
(table 9). The majority of persons who died, 59 
percent, were age 65 or over at time of death, 
while 35 percent were 45-64 ye”ars of age, and 6 
percent were under age 45 (table 9). 
Deaths due to cancers of the breast, diges­
tive, respiratory, and genital organs constitute 
about 70 percent of all deaths from neoplasms 
among both males and females. For males, the 
leading causes of death were cancers of the respi­
ratory organs (33,2 percent), digestive organs 
(26.1 percent), and genital organs (10.1 per-
cent). Among females, the rank order is digestive 
organs (27.8 percent), breast (19.1 percent), 
genital organs (13.4 Percent), and remiratorv 
organs ( 1 i.6 percentj. Except for br&st and 
genital cancer, and several sites, such as intestine 
and rectum, for which the numbers of male and 
female deaths were almost equaI, there were 
more deaths reported for males than females 
for each site. Male deaths were especially pre-
dominant for neoplasms of the buccal cavity and 
pharynx, stomach, respiratory organs, and ur­
inary organs, being 60 percent or more of all 
deaths reported for each of these sites. Except 
for cancers of the respiratory system and the 
small number of men who died of breast cancer, 
women tended to be older than men at age of 
death for most cancer sites. 
Cancers of the sites just listed as the leading 
causes of death for males and for females were 
also the leading causes of death for persons ages 
45-64, and 65 and over. For persons under age 
45, leukemia, other lymphatic and hemato­
poietic tissues, and other and unspecified sites 
made a significant contribution to mortality of 
both sexes. In the 65-and-over age group, higher 
than average proportions of deaths were due to 
neoplasms of the digestive organs, urinary 
organs, and male genital organs. Deaths from 
skin cancers, leukemia, cancers of other lym­
phatic and hematopoietic tissues, other and un­
specified sites, and benign neoplasms, on the “ 
other hand, occurred with relatively high pro-
portions at ages under 65 years. 
About 89 percent of persons dying because 
of neoplasms in 1975 were white (table 10). The 
distribution of deaths by color varied according 
to cancer site, with the ratio of the white popu­
lation to total mortality highest for skin cancer 
(96 percent) and lowest for cancer of the cervix 
uteri (77 percent). 
The number of person-years lost because of 
deaths from neoplasms ‘is given in table 11 by 
age at death, sex, and site. The distributions of 
person-years lost by cancer site are similar to 
those for deaths for each age and sex. But there 
are noticeable differences in the age and sex dis­
tributions of person-years lost and the number 
of deaths, since more person-years are lost when 
a death occurs at a younger age, and women 
have longer life expectancy than men. Almost 
60 percent of deaths from neoplasms occurred 
at age 65 and over, but these deaths produced 
11

only 36 percent of perso’n-years lost. The 35 
percent of deaths occurring at ages 45-64 re­
sulted in 47 percent of person-years lost, while 
deaths under age 45 years, 6 percent of the total, 
caused 17 percent of person-years lost. 
Just as the age distribution of deaths varies 
according to cancer site, so does the age distr­
ibution of person-years lost. Age distributions by 
site are similar for males and females, but there 
is not a single pattern among the sites. For ex-
ample, over half the person-years lost because of 
leukemia resulted from deaths of persons under 
age 45, while the majority of person-years lost 
due to cancers of the buccal cavity and pharynx, 
respiratory orgins, breast, and certain female 
genital organs were in the 45-64-year age group, 
and 67 percent of years lost because of neo­
plasrns of male genital organs occurred among 
persons age 65 years and over at time of death. 
Although more males than females died of 
cancer (54.5 percent), males contributed a little 
less than ‘half of all person-years lost (48.1 per-
cent), owing mostly to the longer life expect­
ancy among women. Still, except for breast can­
cer and malignant neoplasms of the intestine and 
rectum, person-years lost by males exceeded or 
were only slightly less than years lost by fe­
males. Years lost by males exceeded those lost 
by females by the largest amounts for cancers of 
the buccal cavity and pharynx and respiratory 
and urinary organs. 
Another way of looking at the relationship 
of deaths, person-years lost, and age is to con­
sider person-years lost per death (table 12). In 
1975 this measure ranged from a low of 10.1 
years per death associated with male genital or­
gans to a high of 24.3 years per death for bone, 
connective, and other soft tissue, with an aver-
age of 16.1 years for all sites combined. The 
number of person-years per death also equaled 
or exceeded 20 years for the breast, cervix uteri, 
leukemia, and benign neoplasms. Years lost per 
female death exceeded years lost per male death 
for every site, the average difference being 4.1 
yeaxs. Excluding breast cancers, the sex differ­
ence in years lost per death was largest for the 
trachea, lung, and bronchus (5.3 years) and 
smallest for benign neophtsms (1.2 years). 
For all neoplasms,- 43.5 years were lost per 
death at ages under 45 years, 21.5 years at ages 
45-64, &d 9.9 years at age 65 and over (ta 
12). Although years lost per death must ckcre 
as age at death increases, there is considera 
variation among sites within each age group, 
pecially under age 65. The expected year:: Ios 
a person under age 45 dying of leukemia 
ahnost 53 years in 1975, while the average I 
son under age 45 who died of cancer of the 
chea, lung, or bronchus lost an estimated i 
years. For deaths between ages 45-64, the a 
age years lost ranged from a low of 17.3 
male genital organs to a high of 30.5 for ber 
neoplasms. These figures vary somewhat w’ 
males and females are considered separately. 
Multiplying number of deaths by present 
counted values of lifetime earnings (both sp 
fied by age and sex) gives present discoun 
values of ewings lost due to premature mor 
ity. These losses total $15.9 billion a.t a 
percent discount rate and average ah 
$43,000 for each death due to neoplasms. L 
earnings are shown by age, sex, and site in ta 
13 at a 6-percent discount rate. The age distn 
tions of lost earnings vary according to can 
site, depending on the age distribution of dea 
for each site, but are similar for males ; 
fem~es. 
Although almost 60 percent of all dea 
from neoplasms in 1975 occurred at age 65, 
over, this age group accounted for only 36 ~ 
cent of person-years lost and 11 percent of ‘ 
earnings (figure 6), reflecting the lower life 
pectancy and earnings of the elderly. Those i 
sons ages 45-64 years contributed 35 percen, 
deaths from neoplasms, 47 percent of pers 
years lost, and 62 percent of lost earnings. 
individual age 45-64 who dies, whose emni 
were relatively high, might otherwise havt:h: 
significant number of productive years rm-u 
ing; this expkins the high proportions of ! 
years and earnings for this age group. Pers~ 
under age 45 at time of death were respcms] 
for 6 percent of deaths, 17 percent of years 1. 
and 27 percent of lost earnings. Individuals 
der age 45 have remaining many produc 
years at high earnings, therefore yeas lost ~ 
the mortality costs are quite high relative to 
number of deaths. 
For all neoplasms, lost earnings are di: 
buted approximately 60 percent among m: 
12
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Figure 6. Percent distribution of deaths, person-years lost, and 
lost earnings at 6-percent discount rate for all neorzlasms. 
by age: Un;tad States, 1975 
[ 
and 40 percent among females. The male-female 
distribution of lost earnings vanes according to 
site, but except for those sites specific to 
women, intestine and rectum, and beni~ neo­
plasms, over 60 percent of lost earnings results 
from deaths of males. 
It must be remembered, however, that an “ 
inherent limitation of this approach to valuing 
life is the difference in economic reward accru­
ing to groups distinguished by such characteris­
tics as sex and race. The amount of earnings lost 
to women is less than that lost to men, even 
though women account for over half of all 
person-years lost. As seen in figure 7,46 percent 
of deaths from neophssms occurred among 
women, producing 52 percent of person-years 
lost but only 41 percent of lost earnings. This 
occurs because men’s earnings exceed those of 
women at each age and also because women 
have longer life expectancy. Other things being 
equal, the latter factor serves to decrease the 
value, in terms of earnings, of a year lost to 
women compared with men since the average 
woman’s additional years of life produce only 
small amounts of earnings. 
The distributions of deaths, person-years 
lost, and lost earn”mgs among selected cancer 
sites are shown figure 8. For the most part, the 
proportions attributed to a given cancer site are 
similar. Neoplaams of the respiratory organs and 
neoplasms of other and unspecified sites each 
accounted for approximately one-fourth of aII 
deaths, person-years lost, and lost earnings. 
Cancers of the digestive organs were responsible 
for 26.8 percent of deaths, 23.2 percent of 
OEATHS PERSON-YEARS LOST LOST EARNINGS 
* 
Figure 7. Percent distribution of deaths, person-years lost, and lost earnings at 6-percent discount rate for all neoplasms, by sex: 
United States, 1975 
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person-years lost, and 20.3 percent of lost earn­
ings. For cancers of the breast and female genital 
organs, the respective percents are 14.9, 18.2, 
and 15.9; for lymphatic and hemat opoietic tis-
sues the figures are 9.4 percent of deaths, 11.2 
percent of person-years lost, and 12.4 percent of 
lost earnings. 
Economic Costs 
Table 14 summarizes estimated expenditures 
in 1975 for short-stay hospital care and physi­
cians’ services, and indirect costs of murt.dity I 
cancer site. Expenditures for direct costs reflti 
the amount and cost per unit of medical cm­
indirect mortality costs reflect the number, ag 
and sex distribution of deaths, labor fro-c: p; 
ticipation, and earnings. It is estimated th 
in 1975 more than $4.1 billion was spent ~ 
hospital care for neoplasms and over $1.2 b 
lion for physicians’ services. Indirect cotits 
mortality were $12.4 billion at a 10-pmce 
discount rate, or $15.9 billion at 6 percent. 
Aside from the residual categories, ci~ce 
of the digestive and respiratory organs re wlt 
in the highest economic costs. Cancers of t~ 
digestive system accounted for 16 percent 
expenditures for hospital care, 9 percent 
those for physicians’ services, and more th: 
one-fifth of mortality c&ts for neoplasms, Ca 
cers of the respiratory system resulted in few 
expenditures for hospital care (10 percent of t 
total) and physicians’ services (6 percent), b 
were responsible for m’ore than one-fou .th 
mortality costs. These figures reflect the re. 
tively high use of medical care and the Iar 
number of deaths due to cancers of these sit 
Overall there were 15 percent more death:; fro 
cancers of the digestive organs than of the res] 
ratory system; the latter occurred more fl 
quently among men than women and at ymmg 
ages. Consequently, the average indirect cclst p 
cancer death was higher for the respiratory s; 
tern than for the digestive system, both becau 
more productive years were lost and bccau 
earnings are higher for men than women. This 
clearly shown in tables 11 and 2, respec tivei 
Cancers of the breast and female genital i 
gans and benign neoplasms resulted in lower e 
penditures, but these amounted to about or 
third to one-half the costs of cancers of di~;esti 
and respiratory organs. The remaining :anc 
sites, namely cancers of the skin, male };eni 
organs, and leukemia, accounted for rel;ltive 
small amounts of cost compared with oth 
sites. Benign neoplasms are unique in that dire 
costs exceeded mortality costs owing to tl-e ve 
low mortality for this site. Benign neoplasms z 
counted for 22 percent of all short-stay h,>spi 
costs and 41 percent of costs of physician ;’ se 
ices, but are only 2 percent of mortality cos 
Although indirect costs vary by consic.eral 
14 
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amounts for different discount rates, decreasing 
as the discount rate increases, the percent distri­
butions of mortality costs among sites are 
similar. 
SUMMARY AND CONCLUSION 
.. ‘ 
This report detailed the direct and indirect . . 
economic costs resulting from the prevalence of 
,. neoplasms in 1975 in the United States. These 
costs include expenditures for hospital care, 
physicians’ services, and other health care meas­
ures used in prevention, diagnosis, and treat­
ment, and also include the value of output lost 
due to morbidity and premature mortality. 
Neoplasms accounted for 9 percent of the 
total costs estimated for all illnesses. Over $4.1 
billion was spent for an estimated 25.5 million 
days of nonfederal short-stay hospital care. In 
addition, care was received by cancer patients in 
other types of hospitals, such as Veterans’ Ad-
ministration hospitals. Expenditures in these 
hospitals amounted to almost 15 percent of the 
sum for nonfederal short-stay hospitals and 
bring the total cost of hospital care for neo­
plasms to about $4.7 billion. An additional $1.2 
billion was spent for physicians’ services, with 
$672 million or 54 percent of this total for sur­
gery in the hospital and the remainder almost 
equally divided between medical care in the 
hospital ($2 74 million) and office and other vis­
its ($299 million). Almost 371,000 persons died 
from neophisms in 1975. This premature mortal­
ity resulted in an average loss of 16.1 person-
years and almost $43,000 lost per death. Total 
mortality costs amounted to $15.9 billion at a 
6-percent discount rate based on the human cap­
ital	 approach to valuing lives. 
By 1977 the total direct and indirect costs 
for all diseases had increased to $311 billion 
with mortality costs discounted at 10 percent, 
and $346 billion at a 6-percent discount rate. 
Neoplasms accounted for about 10 percent of 
the total for all diseases, ranging from $29 bil­
lion’ to $35 billion. Appendix tables present 
data relating to economic costs of neoplasms by 
site for hospital care, physicians’ services, and 
mortality in 1977. 
Over the years, the cost of neoplasms has in-
creased relative to that of most other diseases. 
Neoplasms accounted for 1 percent of the total 
costs of alI diseases in 1900,45 4 percent in 
1930,46 and 9 percent in 1975.28 Direct costs 
of neoplasms as a percent of all direct costs al­
most doubled between 1900 and 1975, increas­
ing from 2.3 percent to 4.5 percent. More than 
three-fourths of the total costs of neoplasms are 
indirect costs, and these have increased by the 
largest amount, from 0.9 percent of all indirect 
costs in 1900 to 4.3 percent in 1930 and to 11.2 
percent in 1975. This increase in the cost of neo­
plasms relative to all other diseases results from 
the Jincreasing importance of neoplasms as a 
cause of death. In 1900, neoplasms were the 
tenth leading cause of death and accounted for 
less than .3 percent of all deaths#5 In 1930, 
deaths from neoplasms were 9 percent of all 
deaths and the sixth leading cause of deathfi6 
By 1975, only the number of deaths from dis­
eases of the circulatory system exceeded the 
number due to neoplasms, and neoplasms ac­
counted for 19 percent of all deaths.zg 
Future levels of the costs of neoplasms de­
pend on a number of factors including inci­
dence, mortality, and suMval rates; utilization 
and cost of medical care; economic vanabIes 
such as employment and earnings; and the size 
and age distribution of the population. The net 
impact on the future Ievel of costs is uncertain 
since some factors are working to increase costs 
and others, to decrease costs, and the projection 
of trends into the future requires considerable 
conjecture. 
Incidence, prevalence, and mortality are 
three common measures of disease. Although 
there is no nationwide ieporting of cancer inci­
dence in the United States, surveys conducted 
by the National Cancer Institute in 1937, 1947, 
and 1969 show a rising trend in age-adjusted 
rates for men and a falling trend for women.47 
The changes over time differ among sites, how-
ever. For some sites, such as the stomach and 
uterus, cancer has decreased significantly. 
Equally dramatic changes, but in the opposite 
direction, are observed for cancers of the lung. 
Although much lower, time trends in mortality 
rates for the United States released by the Na­
tional Center for Health Statistics parallel the 
trends in incidence rates by cancer site.44 
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Other things being equal, the ~bsolute level 
of direct and indirect economic costs will rise 
with increases in incidence and mortality as 
more medical care is used and output Iost in-
creases. Without any increase in incidence or 
mortality, the increasing size and aging of the 
population will tend to increase both the abso-
Iute cost of cancer, and the cost of cancer rela­
tive to the cost of diseases that occur mainly at 
younger ages, since cancer is mostly a disease of 
the middle and old aged. Under alternative as­
sumptions about future fertifity, mortality, and 
net immigration, the Bureau of the Census pro­
jects future population trends. Of three projec­
tions, the middle one estimates that the United 
States population will increase from 217 million 
persons in 1977 to. 260 million persons in the 
year 200038 While total population will in-
crease by 20 percent, the population age 45 
years and over will increase by 35 percent, from 
67.2 million to 91.0 million people. During this 
period, the population will grow older as median 
age rises from 29.4 to 35.5 years and the pro-
portion age 45 and over increases from 31 per-
cent in 1977 to 35 percent in 2000. 
For all cancer patients combined, there has 
been a small improvement in relative survival 
rates in the past 20 years, with the increase in 
surviwd depending on cancer site.49 Among the 
10 leading cancer sites, the greatest improve­
ments in 5-year relative survival rates were for 
cancers of the bladder and prostate. Cancers of 
the breast and rectum also show some improve­
ment, especially among black patients. Improve­
ments in survival rates may have a mixed effect 
on costs. Indirect costs of mortality will de-
crease, but this trend may be offset to some ex-
tent if increases in use of medical care and in-
direct losses due to morbidity accompany 
increases in suMval time. 
Given the amount of illness that exists, the 
use and cost of medical care for prevention, di­
agnosis, and treatment, wiIl affect the magnitude 
of direct costs. Medical care prices have been ris­
ing rapidly in the United States since the Eco­
nomic Stabilization Program ended in April 
1974. During the period 1974-76, physicians’ 
fees rose 25 percent, and hospital service charges 
for. a semiprivate room increased 33 percent, as 
measured by annual averages of the Consumer 
Price Index.50 There are many components to 
medical care utilization. Hospitzl care, for t:xtirr 
pie, includes room, board, and miscell~wuu 
services, such as laboratory tests, medication. 
intensive care, and surgical facilities. Vari;ltirm 
in use of these hospital services will be reflecte 
in the cost of a hospital stay. For example, th 
average Iength of stay for malignant neoplasm 
in nonfederal short-stay hospitals has decrease 
slowly but steadily in recent years, declining 1. 
days from 14.1 days in 1971 to 12.7 dz,ys i 
lg76:l-52 
Cancer therapy has changed signific anti 
over the years, and it is likely that chang? w“ 
continue to take place. Studying a small nu mbe 
of selected illnesses during two time period: 
Scitovsky and McCall found changes in treat 
ment could be cost raising or cost saving.s3 J’ 
In the years between 1951 and 1964, ther: wa 
a consistent decrease in average length of hospi 
tal stay, and this was the main cost-savin: 
change observed. Between 1951 and 1964, how 
ever, savings due to reduced length of hospita 
stay were ,outweighed by increases in costs du 
to increases in the number of diagnostic test: 
and therapeutic procedures per case, greater US( 
of specialists, and substitution of inpatient fo 
outpatient care. During the period 1964-71., av 
erage Iength of stay continued to decline, whih 
the average number of diagnostic tests increased 
Whereas in the earlier period the net effect o 
changes in treatment was cost raising for the ill 
nesses studied, in the latter period, the net effec 
was cost raising for some conditions and cos 
saving for others. The reasons for cost saving 
vary, although shorter lengths of stay occm-re( 
for all illnesses studied. In addition there was . 
shift to lower-priced tests for cancer of th( 
breast and a decline in the number of physiciar 
visits, X-rays, and laboratory tests for treat ing : 
case of duodenal ulcer. This study show:; th, 
cost of treating an illness may increase or de 
crease as the method of treatment changes. 
Indirect economic costs are directly relater 
to levels of employment and earnings. $;inci 
1970, the proportion employed of the ci~iliai 
‘Changes in treatmentrefers to all changes in iapuc 
of medical services, including new techniques or drugs 
increases or decreases in the use of specialists, Iaborator: 
tests, days of hospital stay, and substitution, for txam 
pie, of outpatient for inpatient care. 
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population age 18-65 years has consistently been’ 
near 70 percent, varying only from a low of 69.1 
percent to a high of 71.2 percent.so Earnings of 
wage and salary workers, on the other hand, 
have been increasing steadily for at least a de­
cade, paralleling the general inflation that has 
taken place in the U.S. economy. Between 1967 
and 1976, median weekly earnings of wage and 
salary workers increased at an average annual 
rate of 6.8 percent .54 
Future economic costs depend on the extent 
of cancer illness, cancer therapies and the at­
tendant use of medical care, medical care prices, 
and economic variables, such as employment 
and earnings. This brief description of recent 
trends indicates the changes that can occur, 
*	 often quite rapidly. Measures that increase 
(greater exposure to environmental carcinogens, 
for example) or decrease (reduced smoking) the 
incidence of cancer will have a like effect on the 
direct and indirect costs that accompany mor­
,	 bidity and mortality, whereas new forms of 
therapy may be cost raising or cost saving. It is : 
likely that eventual scientific breakthroughs in 
prevention and treatment will reduce the threat 
of cancer. In some cases, already existing knowl­
edge, if implemented, would result in significant 
reductions in mortality. For example, mortality 
from lung cancer is many times higher for ciga­
rette smokers than for lifelong nonsmokers. Ex-
smokers also benefit, as mortality from lung 
cancer in this group decreases steadily with 
length of time since having stopped smoking!s 
It would be speculative, however, to antici­
pate future trends and the net effect of changes 
in several factors. A recent effort to project can­
cer mortality in the year 2000 by a Delphi tech-
nic56 illustrates the uncertainty involved in pro­
jecting future trends. A panel of experts, in­
cluding clinicians, cancer clinic administrators, 
researchers, and epidemiologist-biostatisticians, 
was asked to predict death rates from cancer in 
000

the yea 2000. The seven responses ranged from 
a 20-percent increase in cm-rent death rates to a 
90-percent reduction in cancer mortality. The 
expert predicting the Iatter expected new devel­
opments in detection and therapy, a decrease in 
the proportion of the population that smokes, 
and an increase in the use of low-tar cigarettes. 
The expert predicting an increase in mortality 
believed that “increases in occupational exposure 
to chemicals, air and water pollution, food addi­
tives, and nuclear radiation would result in 
higher mortality rates. The median response pre­
dicts a 6.5-percent decrease in total cancer 
deaths from the number that will occur if 1974 
death rates apply in the year 2000, and the 
average of the middle five responses predicts a 
16-percent decrease in cancer deaths. The 
panel’s projections of future cancer mortality 
are quite varied. 
Economic costs are potential benefits of re­
duced cancer morbidity and mortality. Direct 
costs represent resources that could be allocated 
to other uses, and indirect costs are the value of 
idle resources and lost output. Knowledge of the 
costs of specific diseases is an aid to more ra­
tional decisionmaking with respect to allocating 
scarce resources among competing ends. 
Economic costs are, however, an incomplete 
measure of the burden of disease. The quality of 
life is very important, and it is hoped rapid pro­
gress can be made in measuring social costs of ill­
ness and dkease. Further work is also needed on 
economic costs. The future costs of morbidity 
are unknown, estimates are lacking for the costs 
associated with incidence of disease, and al­
ternative approaches to valuing life, such as 
willingness-to-pay, need refinement. Neverthe­
less, the methodology employed, pending im­
provements and refinements, is a means for 
estimating a large part of the burden of disease 
and provides consistent estimates across the 
spectrum of disease categories. 
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Table 1. Estimated direct expenditures and percent distribution of expenditures for all diseases and neoplasms, and expenditures fo 
neoplasms as a percent of all diseases, by type of expenditure: United States, fiscal year 1975 
Expenditures for: 
All diseasesl Neoplasms Neopl isms 
Type of expenditure as e 
Amount Percent Amount Percent percmt in distribution in distribution of illl 
millions millions diseases 
Totel ... .... .. ..... ....... .... .... ....... ... .. .... ... ...... .... ...... ...... .... 2$99,373.2 100.0 $5,278.9 100.0 5. 
-
Hospital care ..... ....... .... .... ...... ..... .... .... ....... ..... ..... .... ...... .. .... ...... 46,414.9 46.7 4,134.2 78.3 8. 
Physicians’ services ... .... .. .... .... .....’.... ..... ...... ..... .. ..... ... ..... .. ..... ..... 22,098.9 22.2 671.2 12.7 3. 
Other professional wwices ..... ..... ..... .. ... ..... ..... ...... ..... ..... ..... ...... 1,453.5 1.5 50.1 1.0 3. 
Drugs and drug sundries ..... .... ...... .... .... ....... ..... ..... ..... ..... .... .. ..... 10,604.9 10.7 202.7 3.8 1. 
Nursing home care ...... ..... ...... ..... .... .. .... .... ...... .... ... . .. .. ... ..... ...... . 9,000.0 9.1 220.7 4.2 2. 
Dentists’ wwices ........................................................................ 7,500.0 7.5 . . . . . . . . 
Eyeglasses and appliances ........................................................... 2,300.0 2.3 . . . . . . . . 
1Based on Social Security Administration’s preliminary eSthSMtM forfiiCdYear 1975. 
2Exclud~S ~n~located ex~e~dit~res for prepayment and administration, government public health activities, other health service! 
research, and construction. 
SOURCE: Peringer, L., and Berk, A.: Costs ofillness anddisease fiicalyear 1975.28 
Table2. Pre*ntvalue oflifetime earnings discounted at6percent endlOpercent, bywxandaga: United States, fiscal year 1975 
Age 
Under 1 year .. .... .. ... ...... ... ..... ...... ... ..... ... ..... ... ... ... ...... ..... ...... .... ..... ..... ....... ... ....... ..... .. 
14 years ... .... ..... .. .. ....... ... .... ... ... ... ......o.. ...... .... .... .. .... .... ....... .. .. ..... ...... .... ...... .. ... ....... .. 
5-9 years ... .... ....... .. ... .. .... ...... .... .. .. .. .. ... .. ..... ...... .... ..... .. ... ...... ..... ..i .. ...... .. ... .... ....... ..... .. 
10-1.4 years ..... ... .... ..... ...... ..... .... ..... .... ... ..... ...... .... ...... .. .. ...... .. ... .... ..... ....... .... ..... ........ . 
15-19 years .... ..... .... ... ....... .... .... ..... ...... ... .... .. ... ...... ..... ..... .... ..... ...... ..... ... ........ .... ....... .. 
20-24 years .. ...... ...... .. ...... .... ...... .. .. ..... ... ...... ..... .... ..... ..... ..... .... .. ..... ..... ..... ... ........ ..... ... 
25-29 years ... .... ...... .... ..... .... ...... .... ... .. ... ..... ..... .. .. .... ..... ... ... .... ...... ..... .... ..... .. .. .... ... .. .... 
30-34 years ... ..... .... .... ...... ..... ..... .. ...... .... .... ..... ..... ... ...... .. ... ..... ... ... ...... ... .... ...... ...... ..... . 
35-39 years ........ .. .. ... ...... ..... ..... ... .... ..... ..... .... .. ... ..... .... ...... .. .. .... .. ..... ..... .... .. ... ....... .... .. 
40-44 years . ..... .... ...... ..... ... .... ...... .... ..... ..... ..... .... ..... .... ...... .. ... .... .. .... ..... ..... .... ...... ...... . 
4549 years . ..... ... .. .. ....... ..... .. .. .... ..... .. ...o.... .... ... ....... .. .. .... .. ..... ..... .... ...... ... ...... ....... ..... . 
50-54 years ...... ..... ... ..... .... ...... ..... .... .... ..... .... ....... .... ..... .... ..... ..... ..... ..... ..... ..... ....... ..... . 
55-59 years ...... .... .. .... ..... .... ..... .... .... ....... ... ...... .... .. ... ...... ...... ... .... .. ..... ..... .... .... ... ..... .. .. 
60-64 years .. .. ...... ... ..... .... .. .. ... ... .. .... ... .... .... ..... ...... ..... ..... ..... ..... ...... .... ...... ...... .... ..... ... 
65-69 years .. ...... ..... .... ...... ... .... ..... .... ..... ..... ..... .. ... ..... .. .... ...... .... ...... .. .... .... ... .. ....... .... .. 
70-74 years ... ... .. ..... ..... .. .... .. .. ...... .... ...... .. .. ..... ..... ... ... ... .. ..... .... ...... ..... .... .. ..... ..... .... .. .. . 
75-79 years .. ..... ...... ... ... ... .... ...... ..... ...... .... ..... .... ...... ..... .... ...... .. .... .... .... ...... .. .... ..... ..... . 
80-84 years ......... ..... .... .... ...... ...... .... ..... .. ... ..... .... .. .. ... ... .. .. .... .. .... ...... .. .. ...... ..... ....... .... . 
85 years and over ... ..... .... ..... ....... ... ...... .. .. .. .... ..... ..... ..... ..... .. .. .. .. .. ...... ... .... . ...... .. ... ...... 
Present value of lifetime earnings 
6-percent discount 10-percent discc,unt 
—— 
Male Female Male Female 
$129,435 $96,303 $37,659 $ :!9,80 
129,794 97,284 38,036 30,22 
157,381 118,002 55,705 44,28 
191,965 143,745 82,066 (;5,1 c 
230,812 171,067 117,367 91,81 
263,308 188,364 152,964 1 ‘I 3,89 
274,496 185,581 173,868 1 ‘I 9,88 
263,864 170,571 176,882 1 ‘i4,05 
241,464 152,391 170,362 105,80 
210,785 132,100 156,719 !)5,4 
171,975 110,049 134,756 }13,23 
127,682 85,799 105,213 1;7,96 
83,144 60,224 72,093 49,84 
42,318 35,957 38,439 30,67 
15,698 18,995 14,048 16,22 
7,239 10,672 6,579 9,35 
3,268 5,541 3,018 4,98 
1,499 2,771 1,410 2,56 
610 1,183 610 1,1. 
—— 
NOTE: Au increase in productivity of 2 percent a year is projected in these calculations. 
SOURCES: Present values at 6 percent are unpublished data obtained from the Public Services Laboratory, Georgetown lJnive 
sity, Washington, D.C. Present vrdues at 10 percent are from Paringer, L., and Berk, A.: Costs of illness and disease fiscal year 1975.2* 
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Table 3, Number and percent distribution of persons by deaths, estimated person-years lost, and sex, and cost and percent distribu­
tion by discount rate and sex, according to age: United States, fiscal year 1975 
Age 
Characteristic 
All Under 45-84 65 year: All Under 45-64 65 years 
ages 45 years years and we, ages 45 years years and over 
DEATHS1 
Number in thousands Percent distribution 
All diY2aS4S 
. 
.! Both wxes .. . .. .. . .. . .. .. .. . .. . .. . .. .. . .. . .. .. .. . . .. .. . .. . .. . .. .. . .. .. . .. . .. . .. .. . .. . .. . .. . . 1,936 23: 463 $,241 100 12 24 64 
— — = = 
Male........................................................................................................... 1,071 151 297 62/ 100 14 2s 5s .	 ,’ Female ... .. . . .. .. . . .. .. . .. . .. .. .. . .. .. .. . . ... . .. . .. . .. .. .. .. .. . .. .. . .. .. ... . . .. .. . .. .. . . .. .. . .. .. . . ... .. . .. .. . S65 S1 166 61 i 100 9 19 71 
I 
Neoplasms 
Both sxes . .. .. . .. .. .. . .. .. .. . .. . .. .. . .. .. . . .. . .. .. .. . .. . .. . .. . .. . .. .. . .. . .. .. . .. . .. . .. .. .. . .. .. . . 388 23 131 211 100 6 36 5s 
Male . .. .. .. . . .. . .. .. . . .. .. .. . .. .. . .. .. . .. . .. .. . .. .. . .. .. . .. .. . . .. .. . .. . .. . .. .. . .. .. . .. . .. . .. .. . .. . .. .. . .. .. . .. . . 199 11 ’117 100 6 59 
Female .. ... . .. . .. . .. . .. . .. .. .. . .. .. . .. . .. . ... . .. . .. .. . .. . . .. .. . .. . .. .. . . ... .. . .. . . .. . .. .. .. . .. . .. .. . .. . .. .. . .. 166 12 ro 94 100 7 Y 57 
PERSON-YEARS LOST 
.’ All diseases 
,, 
Both wxes .. .. .. . .. .. .. . . .. .. . ... .. . . .. . .. .. . .. . .. .. .. . .. ... . . .. . .. .. . .. .. . .. . ... . .. . .. . .. .. . 35,005 15,479 9,248 10,27E 100 44 26 29 
— 
Male .. .. . .. . ... .. .. . . ... . .. . . .. . ... . .. . .. .. . .. .. . .. . .. .. . .. . .. .. . .. . . .. .. .. ... . . .. . .. . .. .. . ... . . ... .. .. . .. . .. .. . 17,344 8,217 3.770 5,357 100 47 22 31 
Famala . .. . .. . . .. . .. . .. .. . .. . . ... . . .. .. . .. . .. .. . .. . . .. ... . .. . .. .. . . .. .. . . .. . .. .. .. . .. . . .. . .. .. . .. .. . .. . .. .. . .. . 17,661 7,262 5,478 4,921 100 41 31 2s 
,. 
Neoplasms 
Both mxes ... . .. . .. . .. . .. . .. . .. .. . .. .. . .. .. . .. .. . . .. .. . . .. . .. .. . .. . .. . . .. .. . . .. .. .. ... . .. . .. .. . .. . 6,545 1,013 2,552 1 ,9s1 100 1s 46 36 
Male . .. .. . .. . .. . . .. .. . .. . . .. .. . .. . . . ... . .. .. . .. . .. . .. . .. .. ... . .. .. . . . ... . .. . . .. .. . .. . .. . . .. .. .. . .. . .. . .. .. . .. .. . 2,770 549 1,244 886 100 20 45 35 
Female ........................................................................................................ 2,775 484 1 ,30s 1,004 100 17 47 36 
LOST EARNINGS 
DISCOUNTED AT 6 PERCENT’ Percent distribution 
All disaaaes 
8oth wxes .. . . .. . .. .. . .. . .. .. . .. . .. .. . .. . .. .. . .. . .. .. .. . . .. . .. .. . . ..... . .. .. . . ... . . .. . .. .. .. . . $87,926 $43,268 &“7,062 I $7,596 100 49 42 9 
62,328 32,093 26,489 3,736 1Oc 61 43 6 
25,59S 11,176 10,563 3,860 10C 44 41 15 
Neoplasms 
All diseases 
15,974 4,342 9,972 1,661 1 Oc 27 62 10 
Male . ... .. .. . . .. .. . .. . .. .. . .. .. . .. .. . . .. .. .. . .. . .. .. . .. . .. .. .. . . .. .. . .. . .. .. . .. . .. .. . .. . .. .. .. . . .. .. .. . .. . .. .. . . 9,454 2,537 6,0S2 S35 100 27 64 9 
Famal@ .. . .. .. . .. .. . .. .. . ... . . .. .. . .. . .. . .. .. . .. .. .. . .. . .. .. .. .. .. .. .. . . .. .. . .. . .. .. . .. . .. .. .. . . ... . .. . .. .. . .. . 6,520 1 ,s05 3,890 825 100 2s 60 13 
LOST EARNINGS 
DISCOUNTED AT 10 PERCENT 16,7S1 =100 40 49 — 11
s 
Both ~XeS .. . .. .. . .. .. .. . .. .. . .. . .. .. . .. .. . .. . .. .. .. .. .. . .. . .. .. . .. .. . . ... . . .. .. . ... .. .. .. . .. 62,527 24,964 30,763 
— 
Male ... .. . .. .. . . .. .. . . .. ... . .. .. . . .. .. . .. .. . ... . .. . .. . .. .. . . .. . ... . .. . .. . . .. .. .. . .. . .. .. . .. . .. .. . .. . .. .. .. . .. .. . 44,210 1S,590 22,249 3,371 100 42 50

Female .. .. ... . .. . . .. .. .. . .. .. . .. . .. .. . .. .. . . .. .. .. . . .. .. . .. .. . .. . .. .. . .. .. . . .. .. . .. . .. .. . .. .. . .. . .. . .. .. .. .. . . 18,318 6,394 8,514 3,410 100 35 46 19

Neoplasms 
Both sexes .. . .. .. . .. . .. .. . .. . .. .. . .. .. . .. .. . .. .. . .. . .. . .. .. . .. .. . .. . . .. .. .. .. . . .. . .. .. . .. . .. . ... . . 12,549 2,S16 8,257 1,476 100 22 66 12 
Malt ............................................................................................................ 7,50s 1,624 5,129 755 100 22 66 10 
Femala . . .. .. .. . .. .. .. . .. .. . .. . .. .. . ... . .. . . .. .. . . .. .. .. . .. .. . .. . .. .. . .. . .. .. . .. .. . .. . .. . .. .. . . ... . . .. .. .. . .. .. 5,041 1,192 3,126 721 100 24 62 14 
— 
1Dastha are those for calendar year 1974. 
NOTE: Numbers snd percents may not add to totals due to rounding. 
SOURCES: Deaths, years lost, and Iost earnings ducounted at 10 percent are from Paringer, L., and Berk, A.: Costs of illness and dmease fiscal year 1975.28 
Lost esmings discounted at6 percent are unpublished data from the Public ServicesLaboratory, Georgetown University, Washington, D.C. 
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Table 4. Estimated indirect costs of illness by disease category, type of cost, and demographic characteristic, according to amc unt in 
. . . millions and discount rate: United States, fiscal year 1975 
Indirect costs 
1O-percent discount 6-percent discount 
Disease category, type of cost, and t 
demographic characteristic Amount Parcent distribution: 
in 
millions By type By demographic 
of cost characteristic 
. . . . 
All disaases 
-7 
. . 
$120,375 100.0 . . . 
.“-
MorMdi~ .... ...... ...... .... ..... ..... ...... .... ....... 57,846 48.1 100.0 
,. 
Currently employ ed ...... .... .... . ... .. .. .... .... ...... ...... 21,303 17.7 36.8 21,303 14.6 36.; 
. ... Females keeping house ... ... ... ..... ... .... ...... .... ..... . 4,384 3.6 4,324 3.0 7.e 
Unable to work ...... .... .. .... ...... ..... ...... ..... ..... ..... . 24,410 20.3 4?2 24,410 16.7 42.; 
Institutionalized ... ..... ..... ..... ..... ..... .. .... ...... ...... . 7,750 6,4 13.4 7,750 5,3 13.’ 
51.962,529 T 100.0 
Male .. ..... ....... .... .... ...... ....... ... ........ ...... .... .. .... .... 44,210 36.7 70.7 
Female . ...... .... .. .. ... .... ....... ..... ..... ..... .. .... .. .... ..... . 18,318 15.2 29.3 
NeorMasms 
. . w-
Total . .. .... ..... .. ... ..... ......... ... .... .. ... ...... $13.654 
Mortidi~ ...... ..... ....... .. ..... ..... ... ... .. .... ..... 1,105 
Currently employed .... ..... ..... ...... ..... .... ....... ...... 422 3.1 38.2 422 2.5 38.Z 
Females keeping house .... ..... .... ....... ..... ...... ..... . 194 1.4 17.6 194 1 7.? 
Unable to work ..... .... .. .. ... ..... ...... .... ..... ..... ..... .. . 440 3.2 39.8 440 H 39.; 
Institutionalized ... .. .. .... .... ......... ..... ... ...... .. ...... . 49 0.4 4.4 49 0.3 4.. 
MoRali~ ...... ..... ..... ..... .. .... .. .... .... ..... ...... 12,549 91.9 100.0 15,974] 93.5 100.[ 
Mele ..... ..... .. ..... .... ...... .. .... ..... ..... .. ... ....... ... ....... . 7,508 55.0 59.8 9,454 55.4 59.: 
Female ....... ... ... ...... ... ... ... .... ....... ...... ..... ...... .... .. 5,041 36.9 40.2 6,520 38.2 40. 
;. 
NOTE: Numbers and percents may not add to totals due to rounding. 
SOURCE: Perirsger, L., and Berk, A.: Coata of Mnesa and disease fiscal year 1975.28 
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Table 5. Estimated costs and percent distribution of all diseases and neoplasms, and neoplasms as a percent of all disaases, by typa of 
cost, according to disease category and discount rate: United Statas, fiscal year 1975 
Typs of cost 
Disease category and discount rate , Al I Direct Indirect cost 
. . 
costs cost ~ 
Total Morbidity Mortality 
All diseases Amount in millions 
10-percent discount ... ...... ...... .... .... .... .. ....... .... ...... ..... .. .. .... .. ..... ..... ... ..... $219,749 $99,374 $120,375 $57,646 $62,529 
6-percant discount .. ... .. ....... ... .. ... .. .... ...... .... .. ... ...... .... ..... ...... ..... ..... ..... .. 245,145 99,374 145,771 57,646 87,925 
Neoplasms 
,’ 10-percant discount .. .. .. .... .... ..... ..... ...... .... .... .. ... .. ..... ...... .... ....... .... .... .... 18,933 5,279 13,654 1,105 12,549 
6.percent discount ... ... .. .... .. ..... .... ..... ...... .. .. ..... ..... ...... ..... ..... .... ...... ..... ... 22,358 5,279 17.079 1,105 15,974 
All diseases Percent distribution 
. 10-percent discount .... .. ...... .. ...... ..... ..... ..... ..... ....... .... ..... ..... ...... .... .. .... .. 100.0 45.2 54.8 26.3 28.5 
6-percant discount .... .. ... ...... ...... .... .... .. ..... ..... ... ..... ....... .... ..... .... .. .... .. .... 100.0 40.5 59.5 23.6 35.9 
“ Neoplasms 
10:percent discount .... ...... .. ...... ....... ... ....... .... ....... . ... ... ...... ..... ..... .. .. ..... . 100.0 27.9 72.1 5.8 68.3 
6-percent discount .. .... .. .. ..... .... ... .. ... ....... .... ..... ..... ...... .... ...... ...... ... ..... ... 100.0 23.6 76.4 4.9 71.5 
Neoplasms Percent of all diseases 
10-percent discount .... ... .... .... ...... .. .. ..... ..... ...... ..... ..... ..... ..... ...... .. ..... ..... 8.6 5.3 11.3 1.9 20.1 
6-percent discount ..... ...... ..... ..... ..... ..... .... ... ... ..... .... ..... ... .. .... ..... ...... ... ... 9.1 5.3 11.7 1.9 18.2 
lEx~ludes ~nallocated &xPen&ltures for prepayment and adminiitration, government public health activities, other health seMces, 
research, and construction. 
SOURCE: Paringer, L., and Berk, A.: Costs of illness and disease fiical year 1975.28 
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Table 6. Days of care in short-stay hospitals for patients with neoplasms, by cancer site, sex, a~d age: Umted States, calendar ye jr 197 
Site 
All neoplasms............................................................................ 
Malignant neoplasms....................................................................... 
Buccel cavity and pharynx ........................................................................ 
Stomach ..............................................................*.... ................................. 
Intestine and rectum ................................................................................. 
Other digastive organs............................................................................... 
Trachea, lung, and bronchus...................................................................... 
Othar respiratory organs............................................................................ 
Skin ........................................................................................................... 
Breast........... ............................................................................................ 
Cervix uteri ............................................................................................... 
Other parts of uterus ................................................................................. 
Other female genital organs....................................................................... 
Male genital organs.................................................................................... 
Urinary organs.................................................................0......................... 
Other and unspecified sites........................................................................ 
Leukemia .................................................................................................. 
Other lymphatic and hematopoietic tissues............................................... 
Benign neoplasmsand neoplasmsof unspecified nature.................. 
NOTE: Numbers may not add to totals due to roun~mg. 
=E 
Days of care in short-stay hospitals in thou=fld!i 
14.694.4 14,301.2 1 I ,203. 
——  
11,080.7 10,212.8 10,398, 
~ ,,,
-. .-
.
. 
.J 
., 
. . 
., 
.; 
... 
. . 
. . 
.. .. 
394.5 265.9 
570.0 339.4 230.; 
2,629.1 1,310.0 1,319.1 
958.8 445.3 513.5 
2,366.5 1,690.5 675.9 
291.7 237,6 
503.9 265.2 238.8 
2,464.7 2,429.1 
743.1 . . . 743.1 
482.3 . . . 482.3 
605.9 . . . 605.9 
1,190.1 1,190.1 . . 
1,113.6 787.3 326.3 
4,109.0 1,934.1 2,174.E 
683.6 371.2 312.4 
1,504.7 648.6 856.1 
; -
3,803.7 
233.6 
253.8 361. 
1,001.3 1,627, 
327.3 631. 
1,252.9 1,113. 
291,2 212. 
1,536.7 
654,7 
279.4 202. 
345.8 260. 
266.3 923. 
406.7 706, 
2,008.7 2,100. 
“378,9 304. 
857.5 647. 
4,088.4-L 805. 
SOURCE Hospital Discharge Survey, Nstional Center for Health Statistics. 
. . 
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Table 7, Estimated hospital expenditures for patients with neoplasms discharged from short-stay hospitals, by cancer site, sex, and age: 
United States, calendar year 1975 
Sex Age 
Site Total 
Male Female Under 65 65 years 
years and over 
Expenditures for short-stay hospitals in millions 
All neoplasms .. .. ... ...... ..... .... .... .. ... .. ... ...... .... ....... ... ...... ... ...... ..... $4,131.6 $1.781.2 $2,370.4 I $2,477.1 $1,654.5 
Malignant neoplasms ... ..... ...... ... ...... .... ..... ..... .. .... .... .... ..... .... ....... ... . 3,215.7 1,542.1 1,673.6 1,699.6 1,516.1 
* Buccal cavity and pharynx .... ..... .... .... ...... .. .. ...... ... .. .... ...... ... ... ... ..... ...... .... 67.0 46.5 � 41.2 
Stomach ...... .... .. ...... ... .... . .... .. .. ... ...... .... .... ... ... .. ... .... .... ...... .... ..... ..... .... ...... 93.2 56.9 36.4 43.3 49.9 
Intastine and rectum .... .... ...... ..... ... ...... ...... ... .... .. .. .. ..... .... .. .. ....... ... .. ... ..... . 425.3 221.8 203.5 170.3 255.0 
Other digestive organs ..... ..... ....... ... ..... ..... .. .. ...... ... ..... .. .... .... ...... ..... ..... .... . 151.0 73.3 77.7 55.1 95.9 
Trachea, lung, and bronchus ... .... .... .... .. .. ..... ....... .... ..... .. .. ..... .. ... ..... ... ....... . 379.5 273.6 105.9 211.3 168.3 
Othar respiratory organs .. ....... .... ..... .... ..... ... ...... .... ...... ... ...... ..... ..... .... .... ... 47.4 39.1 � � � 
Stin .. ...... .... ..... .... .... ... ...... .... ...... ..... .... ..... ... ....... .... ..... ..... .... ...... .... .... .... ... 84.4 45.6 38.8 53.5 30.9 
Braast ... .. .... .... .... .... ..... ..... .... .. ..... .... .... ..... .... .. ..... ... .... ..... ..... .. .... ..... ... ..... .. 344.3 339.0 219.2 125.0 
Carvix uteri ... .... ..... .... ....... .. ... ..... .... ..... ..... ... .. .... ...... ... .... ..... ...... .... ..... .... .. 124.4 . . . 124.4 112.2 � 
Other parts of uterus .. ... .. ...... ..... .... .. ... ...... .... ... .. ... ..... ..... ...... ... .. .... ..... .... .. 78.0 . . . 78.0 48.3 29.7 
Other female genital organs ... ..... .... ...... ..... ... ...... ...... ... .. .. .... ....... .... .... ... ... . 95.5 . . . 95.5 59.6 35.9 
Male ganital organs ....... .... ..... .... ... .... .... .. .. .... ... ....... .... ..... .... .... .. ...... .... ... ... 169.4 169.4 42.2 127.2 
Urinary organs ... ...... ... ..... ..... ...o. ..... .... ..... .... ..... .... .. .. ....... .... .. .. .... ..... .... ..... 177.7 128.1 49+ 70.4 107.3 
Other and unpacified sites . ...... .. .. .. .... ..... .... .... ... .. .... .. .... ..... ... ...... .... ..... .... 593.1 292.1 301.1 313.0 280.1 
Leukemia ...... .... .... .. ... ..... ..... ..... ... ...... ... ... ... .... ..... ...... .. .. .... ... ... .... .... .... ..... 130.7 75.6 55.1 80.9 49.8 
Other lymphatic and hamatopoietic tissues ...... .. .. ...... .... ...... .... ... ... .. .. .. .. ... 254.9 114.9 140.0 159.4 95.5 
Benign neoplasms and neoplasms of unspecified natural ... .... .... ...... 915.8 219.1 696.8 I 777.4 138.4 
NOTE: Amounts may not add to totals due to rounding. 
SOURCES: Days of care. from the Hospital Discharge Suryey of the National Center for Health Statistics; Health Care Financing 
Administration for average per diem chargas to Medicare patients; Third National Cancer Srrrvay of the National Cancer Institute for 
ratio of average daily hospital payments for patients under age 65 to payments for patients age 65 and over. 
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Table 8. Estimated expenditures for and percent distribution of physicians’ services due to neoplasms and percent distribution bY typ 
of visit by cancer site, according to type of visit: United States, calendar year 1975 
I Type of visit I 
Site Office Inpatient hospital Office Inpaoent hospital Office Inpatient ha~i 
Total and Total and Total and 
Otherl Medicel Surgical other 1 Medical Surgical cnherl Medicsl St,rgicd ~ 
All other malignant neoplasms . .. .. . .. . 259.1 50.0 97.5 111.6 20.6 16.7 35.6 16.6 100.0 19.3 37.6 43.1 
Benign neoplasms and neoplasms 
Expenditures in millions Percent distribution ~ site Percent distribution by type of visit 
1 
All neoplasm . ... .. . .. . .. .. . $1,245.6 $289.2 $274.1 I $872.3 100.0 100.0 100.0 I 100.0 100.0 [1 24.0 [ 22.0 54C 
—’ 
Digestive organs . .. .. . ... . .. .. . .. . .. .. . .. .. 114.1 14.0 36.2 63.9 9.2 4.7 13.2 I 9.5 100.0 12.3 37.7 ‘X 
Respirator wrens . . .. .. . .. .. . ... . .. . .. .. 
Skin . .. .. . .. . .. .. . . .. .. . .. .. .. . .. .. . .. .. . ... . .. . . 
Breast . .. . .. . .. .. . .. . .. .. .. . .. . .. .. . .. .. . .. .. .. . . 
Female genital organs .. .. . .. .. . .. .. . .. .. 
78.0 10.0 
46.1 19.4 
84.3 15.4 
73.9 8.0 
25.6 
2.5 
17.8 
8.6 
42.4 
24.2 
51.1 
57.1 
6.3 3.4 9.3 6.3 
3.7 6.5 0.9 3.6 
6.8 5.1 6.5 7.6 
5.9 2.7 3.2 I 8.5 
100.0 
100.0 
100.0 
100.0 
12.9 
42.1 
18.3 
10,6 
32.7 
5.4 
21.1 
11.9 
64.<-
52. 
60.: 
77.7 
Male genital organs . .. .. . .. . .. .. . .. .. . .. .. 51.2 10.2 f4.8 26.2 4.1 3.4 5.4 3.9 100.0 19,9 26.9 51.; 
Leukemia ... . .. .. . .. . .. . .. .. . .. . .. .. . .. . .. .. .. 23.9 8.6 9.9 6.4 1.9 2.9 3.6 0.8 100.0 36.0 41.4 22.[“r61.1 280.4 41.3 54.6 22.3 43.2 1CaJ.o 31.7 11.9 56.4of unspecified sitar .. .. . . .. . . . . .. .. . .. 514.9 163.4 
10ther includes home, telephmte, nursing home, and other. 
‘NOTE Numbers and percents may not add to totals due to roundtng. 1 
SOURCES: Health Care Financing Administration for total expenditures for physicians’ sesvices; National Disesse Therapeutic Index for physicians’, hits by 
site; James R. Cantwell, cd.: Profiles of Medical Practice, American Medicaf Association, Chicago, 1976, for average fees; and Hospital D&chargeSurvey, National 
Center for Health Statistics, for number of short-stay hospitaI discharges with surgery by site. 
Table 9. Number of deaths from neoplasms, by cancer site, sex, and age: United States, calendar year 1975 
Both saxes Male Female 
Site All Under 45-84 65 years All Under 4584 65 years All Undar 45.84 66 wars 
agesl 45 years years and aver agasl 4S yaars years and over agssl 45 Vears years anc over 
Deaths in thousands 
All neoplasms . . .. .. . .. . .. . . .. . . 130.0 217.6 201.9 11.1 70.2 120.6 188.8 11.7 59.8 97.3 
— ——_ 
-
Malignant naoplasms .. . .. .. . . .. . . 128.4 215.3 199.4 10.7 69.4 119.4 168.2 +- 11.3 59.0 95,9 
nature . .. . .. .. . .. . .. .. .. . .. . .. .. . .. . .. . 4.9 O.e 1.6 2.5 2.4 0.4 0.9 1.2 2.5 0.4 0.8 
Buccal cavity and pharynx .. . .. .. . .. . .. . . 8.1 0.3 3.6 4.0 6.7 0.2 2.7 2.8 2.4 0.1 1.1 1.3 
Stomach . .. . . .. . .. .. .. . .. . .. . ... . .. .. .. .. . .. . . ... . 15.0 0.5 4.3 10.3 9.0 0.3 2.8 5.9 6.0 0.2 1.6 4.4 
Intestine and rectum . .. . . .. . .. .. . . .. .. .. . .. . 50.1 1.4 13.7 35.0 24.2 0.7 7.1 16.4 25.9 0.7 6.6 16,6 
Other digestiva organs .. .. . .. . .. .. . .. . .. . .. . 34.6 0.9 11.6 22.0 19.6 0.6 7.4 11.7 15.0 0,3 4.3 10.3 
Trachea, lung, and bronchus .. . .. . .. .. .. 82.0 2.7 36.5 42.9 63.4 1.7 27.4 34.3 18,6 0.9 9.1 6.6 
Other respirator organs .. .. . .. . .. .. .. . .. . 4.6 0.2 2.0 2.4 3,7 0.2 1.6 1.9 1.0 0,1 0.4 0.6 
8mse, connective, and other soft 
tissue .. . .. . .. . . .. . .. .. . .. . .. . . .. . .. . .. . .. .. .. .. . .. 3.2 0.8 1.0 1.4 1.7 0.5 0.6 0.7 1.5 044 0.5 0.7 
Skin . .. .. . .. . .. . .. . . .. .. . . .. . .. .. . . .. . .. . .. .. . .. .. .. . 5.3 0.9 1.9 2.5 3.1 0.5 1.2 1.3 2.2 0,4 0.7 1.1 
Breast .. .. . .. .. .. .. . . . .. .. . .. . .. . .. . .. .. . . .. .. .. . .. . 32.4 2.7 14.5 15.2 0.3 0.0 0.1 0.2 32.2 2.7 14.4 15.0 
cervix uteri .. . .. . .. . .. . .. . . .. . .. . .. .. . .. . .. .. . .. . 5.6 0.9 2.5 2.2 . . . . . . . . . . . . 5.6 0.9 2.5 2.2 
Other parts of uterus . . . .. .. . .. . .. . .. . .. . .. . 5.6 0,2 1.6 3.7 . . . . . . . . . . . . 5.6 0.2 1.8 3.7 
Other female genital organs . .. .. . . .. .. .. 11.4 0,7 5.0 . . . . . . . . . 11.4 0.7 6.0 5.6 
Male genital organs .. .. . . . .. .. . .. . . .. .. . .. . .. 20.4 0,6 2.6 1; 20.4 06 2.6 17.3 ..: . . . . . . . . . 
Urinary organs .. . . .. . .. .. .. . . .. . . .. .. . .. . .. .. . . 16.5 0.5 4.6 11.4 11.0 0.3 3.2 7.5 5.5 0.2 1.3 4.0 
Other and unspecified sites . . .. .. . .. .. . . . 36.1 3.5 12.7 19.9 18.3 1.9 7.0 9.4 17.8 1.6 6.7 10.4 
Leukemia .. .. .. . .. . .. . .. . .. .. . . .. . .. .. . . .. . .. . .. .. 14.8 3.0 3.5 8.2 8.4 1.7 2.1 4.6 6.4 1.3 1.4 3.6 
Other lymphatic and hemato-
poietic tissues .. .. .. . . ... . . .. . . .. . .. .. . . .. .. .. 20.0 2.3 6.5 11.2 10.8 1.4 3.8 5.6 9.2 0.6 2.7 5.5 
6enign neoplasms and 
neoplasms of unspecified 
_L 1.3 
lTotaIs include persons of unknOwn ages. 
NOTE? Numbers may not add to totals due to rounding. 
SOURCE: Division of Vital Statistics, National Center for Health Statistics. 
28 
. 
Table 10. Number and percent distribution of deaths from neoplasms by cancer site, according to color: United States, calendar year 
1975 
Color 
Site 
. . 
All neoplesms.............................................. 
.. 
Melignent neoplasms........................................ 
Buccal cavity and pharynx .......................................... 
Stomech ...................................................................... 
Intestine and rectum ................................................... 
Other digestive orgens................................................. 
Trechea, lung, end bronchus ..................................... . 
Other respiratory orgens............................................. 
Total White All Total White All ~ 
other other 
Deaths in thousands Percent distribution by site 
I 
370.6 II 329.9 40.8 100.0 100.0 100.0 
365.7 II 325.5 40.2 98.7 98.7 98.5 
* 
8.1 7.1 1.1 2.2 2.1 2.6 
15.0 12.6 2.4 4.0 3.8 5.8 
50.1 45.7 4.4 13.5 13.8 10.7 
34.6 28.8 4.8 9.3 9.0 11.8 
Percent distribution 
by color 
100.0 II 89.0 11.0 
100.0 II 89.0 1!.0 
100.0 86.6 13.4 
100.0 84.0 16.0 
100.0 91.2 8.8 
100.0 86.1 13.9 
100.0 89.3 10.7 
100.0 87.0 13.0 
100.0 87.5 12.5 
100.0 96.2 3.8 
100.0 91.1 8.9 
100.0 76.8 23.2 
100.0 86.0 14.0 
100.0 92.2 7.8 
100.0 64.3 15.7 
100.0 92.1 7.9 
100.0 88.4 11.6 
100.0 91.8 8.2 
100.0 90.5 9.5 
100.0 87.8 12.2 
Bone, connective, and othar soft tissua....................... i 
Skin 0.,,,....................................................................... 
Breest.......................................................................... 
Cervix uteri ................................................................. 
Othar parts of uterus................................................... 
Othar female genital organs......................................... 
Mele genital orgens...................................................... 
Urinary organs ............................................................ 
Other and unspecified sitas......................................... 
Leukemia .................................................................... 
Other lymphatic and hematopoiatic tissuas................. 
Benign neoplasms and neoplasms of 
unspecified nature ......................................... 
82.0 73.3 8.8 22.1 22.2 21.5 
4.6 4.0 0.6 1.3 1.2 1.5 
3.2 2.8 0.4 0.9 0.9 0.9 
5.3 5.1 0.2 1.4 1.5 0.4 
32.4 28.6 2.9 8.8 9.0 7.0 
5.6 4.3 1.3 1.5 1.3 3.1 
5.6 4.9 0.8 1.5 1.5 1.8 
11.4 10.6 0.9 3.1 3.2 2.1 
20.4 17.2 3.2 5.5 5.2 7.8 
16.5 15.2 1.3 4.5 4.6 3.2 
36.1 31.9 4.2 9.7 9.7 10.4 
14.,8 13.5 1.2 4.0 4.1 3.0 
20.0 18.1 1.9 5.4 5.5 4.6 
4.9 4.3 0.6 1.3 1.3 1.5 
NOTE: Numbers and percents may not add to totals due to rounding. 
SOURCE: DivMon of Wet Statistics, National Center for Health Statistics. 
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Table 11. Person-years lost due to neoplasms, by cancer site, sex, and age: United States, calendar year 1975 
-
I Both SeXeS I Male I Female 
Site 
., 
,.’, 
All neoplasm . ............ ......... 
. . Malignant neoplasm .. .... ... .... ... 
. . . 
.: Buccal cavity and pharynx ........... ....... 
,, StOma& ......... .... ... ........... .............. .....
..-: 
. . Intestine and rectum ........ .. .. ........... .... 
. . 
.4 Other digsqive organs ........... .............. 
.: Trashea, lung, and bronchus .. .... ......... 
Other respirator organs ......... ............ 
Fsone,connective, and other soft 
. . 
tissue ..... .......... ................ ................ . 
,. Skin .............. ... ...... ... ................. ......... 
ereaw .... ............ .. .. .... ....... .. ........... ..... . 
Cawix uteri ......... .......... .... .... ..... ..... .. .. 
Other parts of uterus .......... ... .............. 
Other female genital organs.... .... ......... 
Male genital organs..... ............... .. ........ 
.-’ Urinary organs ...... .......... ............ ...... .. 
. . 
Other and unspecified sites ................. 
.-
kukemia ....... .. ...... .. ........... ..... ........... 
Other lymphatic and hemato­
,- poietic tissues... ... .......... ............ ...... . 
. . 
8enign neoplasrm and 
neoplasms of unspecified 
nature ........ ... .. ...... .... .......... ... 
. . 
NOTE: Numbers may not add to 
SOURCE Number of deaths and 
“. 
., 
., 
All Under 45-s4 65 years 
ages 45 years years and over 
Person.vears lost in thoussnds 
5,9s4.4 992.9 2,796.6 2,164.9 2,664.9 458.5 3,039.5 
-
-
5,639.5 952.7 2.746.8 2,139.8 2,80S.6 438.3 aa 3,029.9 
130.4 
2U1.3 
12.1 
16.8 
77.8 
87.8 
40.5 65.3 
112.4 z 51.6 52.3 26.2 51.2 45.1 S8.9 4.6 7.9 “ 26.2 35.6 14.3 45.6 
582.7 53.6 268.1 3% 299.6 26.0 131.5 142.2 383.1 27.6 167.6 197.9 
493.4 35.9 235.9 221.4 256.3 21.3 137.4 107.5 227.1 14.6 98.5 113.9 
1,261.4 92.3 736.4 432.e a9a.5 57.1 613.3 328.o 262.9 35.2 223.1 1 M.6 
72.0 8.2 40.4 23.3 53.3 5.8 29.6 17.a 18.7 2.4 10.6 5.6 
78.0 42.8 21.2 14.1 38.3 22.1 10.1 6.2 39.7 20.7 11.1 7.9 
101.9 36.7 41.8 23.5 56.0 20.3 24.3 11.5 45.9 16.4 17,5 12.0 
648.8 109.3 365.5 174.1 3.7 0,5 1.8 1.4 645.1 108.6 363.7 172.7 
124.7 35.8 63.4 25.5 . . . . . . . . . . . . 124.7 35.8 83.4 25.6 
90.6 6.8 41.9 41.9 . . . . . . . . . . . . 90.6 6.8 41,9 41.9 
22o.3 28.9 123.4 66.0 . . . . . . . . . . . . 220.3 28.9 123.4 68.0 
207.1 23.7 44.1 139.3 207.1 23.7 44.1 139.3 . . . . . . ,.. . . . 
220.6 21.5 92.4 106.7 136.2 11.3 66.2 64.7 84.4 10.2 32.2 42.0 
641.0 166.1 273.2 201.7 304.9 85.6 133.1 86.3 336.1 60.5 140.1 116.4 
312.7 161.1 74.8 76.7 164.6 86.7 39.2 38.7 148.1 74.4 35.7 38.0 
352.6 101.1 137a 113.8 183.3 al.5 71.5 50.3 168.3 39.6 66.1 83.5 
114.9 40.2 I 49.7 25.0 63.3 20,2 24.8 10.3 59.6 14,7 
JXl_Xl 
tals
due to mundins. 
Iment ~tfe tables for 197s from the DMsion of Vital Statistics, National Center for Health Stat M ic$. 
., T8ble 12. Person-yeers lost per death due to neoplasms, by cancer site, sex, and age: United States, calendar year 1975 
-
8oth sexes Male Female 
Site 
All Under 45-64 65 years All Under 45-64 65 years All Under 45-84 65 ywrs 
ages 45 years years and over ages 45 years years and over ages 45 years years and IIvsv 
— 
Person-years lost per death 
. . All neoplasms .. .. .. . .. . .. .. . .. . .. .. . . 9,9 14.2 41.3 18.9 46.6 24.6 11.1 
— —— 
= 
Malignant neoplasm . .. . .. .. . . ... . . ... . l+++ 
9.9 14.1 41.1 18.7 
* 
45.4 24.5 11.1 
neoplasms of unspecified

nature .. . .. .. . .. .. . .. . .. . .. . .. .. . .. . .. .. . . .. . 23.2 49.5 30.5 1O.c 22.6 47.8 29.1 8.8 23.8 51.4 32.0 11.0

Buccal cavity and pharynx .. . .. . .. . .. .. . .. . .. . . 16.0 38.5 20.6 1 O.c 15.0 35.9 19.1 9.4 18.4 43.8 24.4 11.3 
Stomach .. . .. .. . .. .. .. . ... . . .. .. .. . . .. .. . .. .. . .. . . .. .. . . 13.4 37.2 20.5 9.4 12.6 34.1 1 B.6 8.7 14.8 41.4 24.1 10.4 
Intestine and rectum . .. . .. .. .. . . .. . .. .. . .. .. . . .. . . 13.8 38.3 21,1 9.7 12.4 35.8 18.6 8.7 14.8 40.9 23.9 10.6 
Other digestive organs . .. .. .. .. .. .. .. . .. .. . . .. .. . 14.3 38.4 20.3 10.1 13.6 35.9 18.7 9.2 15.2 42.7 23.0 11.0 
Trachea, lung, and bronchus . .. . .. . .. .. .. . . .. . 15.4 34.8 20.2 10.1 14.2 32.7 18.7 9.6 19.5 39.0 24.6 12.1 
Other respiratory organs . .. .. . .. . .. . .. . ... . . .. . . 15.5 38.8 19.9 9.7 14.6 35.7 18.7 9.3 18.1 45.3 24.4 11,3 
Bone, connective, and other soft 
tissue .. .. . .. . .. .. . . .. .. . .. .. .. . . .. . .. .. . . .. .. . .. .. . .. . . . 24.3 51.4 21.9 1O.c 23.0 47.5 19.6 9.1 25.7 56.3 24.4 11.0 
Skin .. .. . . .. .. . . .. .. .. . .. . .. .. . . .. . .. . .. .. .. . . .. .. .. . . .. .. . 19.3 40.6 21.9 g.f 18.2 37.9 20.0 8.7 20.9 44.7 25.3 10.5 
Breast .. . .. .. ... . .. .. . .. . .. .. ... .. .. . ... . . ... ... . . .. . .. .. . 20.0 40.2 25.1 11.: 13.4 35.7 18.2 8.5 20.1 40.3 25.2 11.6 
Cervix uteri .. . .. . .. .. .. . .. .. . .. . .. .. . . .. .. . .. .. . .. . .. . . 22.5 41.3 25.6 11.E . . . . . . . . . . . 22.5 41.3 25.6 11.5 
Other parts of uterus .. .. . .. . .. .. . . .. . .. .. .. . .. . .. 16.2 42.o 23.7 11.4 . . . . . . . . . . . . 16.2 42.0 23.7 11.4 
Other female genital organs .. . .. . .. . .. .. . .. . .. 19.3 42.6 24.9 11.7 ,.. . . . . . . . . . 19.3 42.6 24.9 11.7 
., Male genital organs ... . .. . .. .. .. . . .. .. . . .. . .. . .. .. . 10.1 42.6 17.3 8.C 10.1 42.6 17.3 8.0 . . . . . . . . . . . . 
Urinary organs .. ... . . .. .. . . ... . .. ... . . . .. .. . .. . .. .. . . 13.3 43.3 20.1 9.: 12.4 38.7 18.5 8.7 15.3 50.0 24.0 10.8 
Other and unspecified sites .. .. . .. . .. .. .. .. . .. . 17.8 47.4 21.5 10.1 16.6 44.5 19.1 9.1 18.9 50.9 24.4 11.1 
Leukemia . .. . .. .. . .. . .. . .. .. . .. . .. .. . .. . .. . .. .. . .. .. .. .. 21.2 52.9 21.3 9.4 19.6 49.7 19.0 8.5 23.2 57.0 24.7 10.5 
Other lymphatic and hemato. 
poietic tissues .. .. .. .. . .. . .. . .. . .. .. . . .. .. . .. . .. .. . . 17.7 44.7 21.2 10.: 17.0 42.7 19.0 9.0 18.4 46.2 24.2 11.3 
Benign neoplasms and 
I --L 
SOURCE: Number of deaths and current life tables for 1975 from the Divi: m of Vital Statistics. National Center for Health Statistics. 
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Table 13. Present discounted value of loat earnings due ‘to naoplasms at 6-percent discount rata, by cancar site, sax, and age: Unitad States, calendar year 1975 
Both sexes Male Female 
Site All Under 45-64 65 years All Un&r 4s64 65 yaars All Under 45-64 65 years 
ages 45 years years and over ages 45 years years and ovar ages 45 years years and over. 
Loat earnings in millions 
All neoplasm . ............... ... $15,866.7 $4,252.0 $9,914.5 $1,702.2 $9,406.8 $2,511.9 $6,035.7 $859.2 $6,461.9 $1,740.1 $3,878.8 $843.0 
Malignant neoplasrns ............. 15,529.8 4,103.0 9,743.9 1,882.9 9,203.8 2,420.7 5,931.9 851.1 6,326.0 {,682,3 3,812.0 831.8 
L 
Buccal cavity and pharynx ........... .... 408.4 63.0 311.0 34.4 312.9 47.2 242.7 22.9 95.5 15.8 68.3 11.5 
StOmati ........................................... 486.8 66.7 327.6 70.6 334.7 60.1 236.1 38.5 152,1 26.6 91.4 32.1 
Intestine and rectum ........................ 1,510.3 269.4 990.1 250.8 868.1 170.2 590.8 107.1 642.2 99.2 399.3 143.7 
Other digestive organs ...................... 1,228.7 185.0 869.6 174.2 845.5 134.5 623.9 87.2 383.2 50.5 245.7 87.0 
Trachea, lung, and bronchus ............ 3,826.1 516.9 2,929.5 379.6 3,020.3 389.5 2,341.9 288.9 805.8 127.4 587.6 9C:7 
Other respiratory organs .................. 226.3 43.9 162.9 19.5 185.9 36.1 134.7 15.1 40.4 7.8 28.2 4.4 
Bone, connective, and other soft 
tissue ............................................. 254.5 165.2 78.2 11.1 162.1 107.7 49.4 92.4 57.5 28.8 6.1 
Skin ................................................. 376.5 189.3 169.8 11.4 261.2 130.8 121.7 %’ 115.3 58.5 48.1 8.7 
Breast ....... .............. ...................... .... 1,536.6 398.4 996.7 141.5 12.6 3.2 8.3 1.1 1,524.0 395.2 988.4 140.4 
Cawix uteri ...................................... 327.0 130.2 176.0 20.8 . . . . . . . . . . . . 327.0 130.2 176.0 20.8 
Other parts of uterus ........................ 163.0 24.4 105.0 33.6 . . . . . . . . . . . . 163.0 24.4 105.0 33.6 
Other female genital organs.............. 488.9 101.2 331.0 56.6 . . . . . . . . . . . . 488.9 101.2 331.0 56.6 
Male genital organs........................... 402.3 140.2 172.9 89.2 402.3 140.2 172.9 89.2 . . . . . . . . . 
Urinary organs ....... .......................... 521.9 91.9 351.5 78.5 380.5 62.9 269.4 48.2 141.4 29.0 82.1 303 
Other and unspecified sites .............. 1,807.2 657.4 989.8 160.0 1,118.7 424.2 623.4 71.1 688.5 233.2 366.4 88.9 
Leukemia ......................................... 897.6 565.6 277.6 54.6 583.4 373.1 182.7 27.7 314.2 192.5 94.9 26.9 
Othar lymphatic and hemato-
poietic tissues........ ........................ 1.067.6 472.3 504.8 90.5 715.5 341.0 334.0 40.5 352.1 131.3 170.8 50.0 
Benign neoplasms and 
neoplasms of unspecified 
nature ........ ......................... 338.9 148.9 170.6 19.3 203.0 91!1 103.8 8.1 135.9 57,8 66.8 11.2 
NOTE: Numbers may not add to totals due to rounding. 
SOURCES: Number of deaths from the Division of V]tal Statistics. National Center for Health Statistice.
. 
and Dresent
. 
values of Ufatime earninga from the Public Services LaboratorY. 
Georgetown University, Washington, D.C, 
tJ 
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Table 14. Estimated amount and percent distribution of expenditures for short-stay hospital care and physicians’ services jue t{ 
neoplasms and indirect costs of rnortalityat 6-and 10-parcent discount rrites, by cancer site: United States, calendar year 19;6 
. . 
,. 
,. 
. ..- “ 
. 
.-.’ 
. 
. . “ 
. . 
,. 
. . 
Site 
All neoplasms ...... ..... .... ........ .. .. .. . ...... ..... .... .. .... ..... ...... ...... ... .. .... ..... ... 
Digestive organs ... ..... ...... ..... .. ... ..... .... ....... ... .. .... .... ....... .... ... .. ..... .. ... ..... ....... ... .... 
Respiratory organs .. ... .. .... ..... ...... .... ... .. .... ...... ..... ..... .... ........ ... ...... .... .. .. .... ... ... .. .. 
Skin ... ..... ... . ...... ..... ..... ... ... ..... ..... .... ...... ..... ..... ..... ...... .... ..... ... ... .... ..... .... .... .... ... . 
Breast . ...... .... ...... .... . ....... ...... .. ....... ... .. ... .. .... ...... .... ...... ..... ..... .... ....... .... ...... .. .. ... .. 
Female genital organs ...... ... ... . ... ... ..... .... ...... ... ..... .... .... ..... ....... .... .... ...... ...... .. ... ... 
Male genital organs . ... .... .... ... ..... ... ........ .... .... ..... ... ... .. .... ..... ..... .... .. .... .... ...... .. .....4 
Leukemia .... ...... ... ... .... ...... .... ...... .... ..... .... ..... .. ..... .. ... ...... ..... ..... ..... ..... .... .. .... ...... 
All other malignant neoplasms .... .. ... ..... ..... .... ....... ..... .... ...... ...... ..... ..... .... ...... ..... 
Benign and unspecified neoplasms .... ... .. ... ...... ...... ..... .. ... ... .. ....... ..... ..... ..... .. .... .. . 
All neoplasms ... ...... .... ..... .... .. .... ... ... ..... ... .. ... ... ... .. ...... .... ..... .... .. ...... .... 
Digestive organs ... ... ...... .... .. ... ..... .. ... ...... ..... ..... ...... ..... .... .. ..... .. .... .. ... .... ...... .. ... .. . 
Respiratory organs .... ..... ...... .. . ...... ... ..... ...... ....... .... ...... .. ... ..... ..... ..... ... .... .. .. ..... .. . 
Skin ....... .... .... .. .... .. .... ...... ... ..... .. .... .... .... ... .. ... .... .... ..... ....... ...... ...... ... ........ .. ... .... . 
Breast .... ...... ...... .... ....... ..... .... ..... ..... .... .. . .. ... .. ...... .... .. .. ... ..... .... ....... ... ...... .. ..... .... . 
Female genital organs ... ..... ..... .... ..... .... ...... .... .. .... ... .. ... ... ....... .... ..... .... ........ ... ..... . 
Male genital organs .... ..... ... ..... ...... ... ... ... ..... ...... ..... ..... .... ...... ...... ..... ...... ..... ...... ... 
Leukemia ... .... ....... ... .. .. ... ..... .... ..... ..... .... .... ...... ...... .. .... .... ..... .... ... .... ...... .... ........ . 
All other malignant neoplasms ... ... .. .. .. .... ...... ..... ... ... ... ... ..... .. .. .... ..... .... .. .. .... ....... 
Benign and unwecified neoplasms .. ... ..... .. .... ....... ..... .... ...... .... ... ..... .. .. ..... .. .... ..... 
NOTE: Numbers and percents may not add to totals due to rounding. 
Expenditures for: Indirect costs ofI mortality 
SzEEEIz

Amount in millions 
$4,131.6 I $1,246.6] $15,B68.71 
669.5 114.1 3,225.B 
426.9 78.0 4,052.4 
64.4 46.1 376.5 
344.3 84.3 1,53&6 
297.9 73.9 978,9 
169.4 51.2 402.3 
130.7 23.9 897.6 
1,082.7 259.1 4,059.6 
915.8 514.9 338.9 
percent distribution 
100.0 100.0 100.0 
16.2 9.2 20.3 
10.3 6.3 25.5 
2.0 3.7 2.4 
8.3 6.8 9.7 
7.2 5.9 6.2 
4.1 4.1 2.5 
3.2 1.9 5.7 
26.4 20.8 25.6 
22.2 41.3 2.1 
I 
$12,448.( 
~ 
2,641.: 
3,344.! 
282. 
1,199., 
763.: 
319.. 
595.< 
3,089.c 
213.: 
100.1 
=-
21; 
26.: 
2.: 
9.t 
6. i 
2.t 
4.E 
24.[ 
1.; 
SOURCES: Table 7 for expenditures for short-stay hospital care; table 8 forexpenditures forphysicians’ semices; table 13 for 
tidkect costs ofmotiality at6percent; same sources asti table 13 forinduect costs ofmortalityat 10 percent. 
32 
I 
I

I

l’. 
, 
..! 
— ——- .— -. 
APPENDIX 
CONTENTS 
Methodology and Economic Cats, 1977............................ ............................................................... .....

Dmect Costs ......................... .............................................................................................................

Indirect costs .................................................................................................... ...............................

Economic Costs of Cancer by Site in 1977 ........................................ .................................. ............

I. 
IL 
III. 
Iv. 
v. 
VI. 
VII. 
LIST OF APPENDIX TABLES 
Days of care for patients with ncoplasrns discharged from short-stay hospitals, by cancer site, 
sex, and age: United States, calendar year 1977 ............................................................................

Estimated hospital expenditures for patients with neoplasms discharged from short-stay hospi­
tals, by cancer site, sex, and a= United States, calendar year 1977 ..................................... ........

Estimated expenditures for and pement distribution of physicians’ services due to ncopkwns by 
cancer site, according to type of visit: United States, calendar year 1977 .....................................

Number of deaths from neoplasms, by cancer site, sex, and age: United States, calendar year

1977 ..............................................................................................................................................

Person-years lost due to ncoplasnis, by cancer site, sex, and age: United States, calendar year 
1977 ..............................................................................................................................................

Person-yearn lost per death due to neoplasms, by cancer site, sex, and age: United States, calen-
Presmt value of lifetime earnings discounted at 6 percent and 10 percent, by sex and age: United

States, calendar year 1977 ........................................................................................................ .....

VIII.	 Present discounted value of lost earnings due to neoplasms at 6-percent discount rate, by cancer

site, sex, and age: United States, calendar year 1977 ......... ...........................................................

IX..	 Present discounted value of lost earnings due to neoplasms at 10-percent discount rate, by cancer

site, sex, and age: United States, calendar year 1977 ............................................................."......

x.	 Estimated amount and percent distribution of expenditures for short-stay hospital care and phy­

sicians’ services due to neoplasms and indirect costs of mortality at 6- and 10-percent discount

rates, by cancer site: United States, calendar year 1977 ................................................................

34 
34 
36 
38 
38 
39 
39 
40 
40

41

41

42

42 
43 
33 
APPENDIX 
METHODOLOGY AND ECONOMIC COSTS, 1977 
Direct Costs 
The methodology and data used to estimate 
economic costs of disease have been explained in 
detail by Rice,2g Cooper and Rice,30 and Parin­
ger and Berk.zs National health expenditures, 
by type of expenditure, have been published 
annually by the Social Security Administration 
and will be released by the Health Care Financ­
ing Administration in the future. Total expendi­
tures for hospital care, physicians’ services, and 
the other direct costs of illriess are distributed 
by diagnosis according to utilization and costs, 
using consistent data sources for each diagnosis. 
Expenditures in community hospitals, for ex-
ample, are allocated to a diagnosis in proportion 
to the number of days of care attributable to the 
diagnosis weighted by the expense per patient 
day. Similar procedures are applied to the other 
categories of dkect costs to distibute the total 
among diagnoses. In each case, utilization, 
weighted by unit cost where possible, deter-
mines the share of total expenses assigned to 
each diagnosis. 
The cancer sites discussed in this report and 
their ICDA-8 codes (Eighth Revision Interna­
tional Classification of Diseases, Adapted for 
Use in the United States)57 are as follows: 
Site ICDA Code 
Buccal cavity and phaxynx .............140-149 
Digestive organs and peritoneum: 
Stomach ..................................... 151 
Intestine and rectum ..................152-154 
Other ..................................150,155-159 
NOTE: A list of references follows the text. 
Respiratory system: 
Trachea, lung, and bronchus ....... 162 
Other ...................................160-161, 16: 
Bone, connective, and other soft 
tissue ............................................ 170.171 
Breast ............................................. 174 
Genital organs, female: 
Cervix uteri ................................ 180 
Other parts of uterus ..................181-182 
Other .......................................... 183-184 
Genital organs, male ....................... 185-187 
Urinary organs ................................ 188-189 
skin ................................................ 172-173 
Other and unspecified sites .............190-199 
Lymphatic and hematopoietic tis-
sues: 
Leukemia ................................... 204-:?07 
Other ..............“.............200-203,208-209 
Benign neoplasms and neoplasms of 
unspecified nature ..........210-228. 230-:?39 
Hospital care by cancer site.–Expenditures 
in short-stay hospitals are estimated by multiply­
ing the number of days of care, as estimated by 
the Hospital Discharge Survey of the Natio Qal 
Center for Health Statistics, by the average c>st 
per day. For the population age 65 years and 
over, average per diem charges to a large sample 
of Medicare patients5g are used as the aver:lge 
cost per day. For those under age 65, an e:xi-
mate of average costs is obtained by adjusting 
average Medicare charges by the ratio of.average 
daily payment for patients under age 65 at time 
of diagnosis to average daily payment for pa­
tients age 65 and over observed in the Third 
National Cancer Survey of the National Cancer 
Institute.sg This procedure is repeated for each 
cancer site. . 
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Expenditures in nonfederal short-stay hos­
pitals for all neoplasms obtained by this method 
are about 13 percent higher than the share of 
hospital expenditures in table 1 attributed to 
short-stay hospitals. Of the $4.1 billion shown 
for hospital care in table 1, only $3.6 biIIion was 
spent in short-stay hospitals; the remainder is 
the cost of care in other types of hospitak, such 
as those of the Veterans’ Administration. Most 
of this difference between expenditures in short-
stay hospitals in tables 1 and 7 can be explained, 
however. Since the computation of the estimates 
in table 1, the Health Care Financing Adminis­
tration has revised upward by 4 percent its esti­
mate of national health expenditures for hospi­
tal care in fiscal year 1975, the figure used to 
obtain expenditures in table 1. Further, esti­
mates in this section are for calendar year 1975 
rather than fiscal 1975.Hospital care expendi­
tures increased 15 percent between fiscal 1975 
and fiscal 1976.60 If this increase were uniform 
over time, expenditures in calendar 1975 would 
be 7 to 8 percent greater than in fiscal 1975. 
Thus, all but 1 to 2 percent of the difference in 
the two estimates can be explained. The two es­
timating procedures yield quite consistent 
results. 
Physicians’ services by cancer site.–In previ­
ous studies, the magnitude of expenditures for 
physicians’ services by diagnosis were deter-
mined by distributing the Social Security Ad-
ministration’s estimate of national expendi-
tures60 according to the proportion of physician 
visits reported for each diagnosis by the National 
Disease and Therapeutic Index.d This assumes 
every visit has the same cost; office and hospital 
visits are given equal weight, for example. 
Further, national expenditures for physicians’ 
services inckde payments for surgery, which are 
also allocated to diagnoses according to the 
relative number of physician visits. This method 
understates expenditures for physicians’ services 
related to neoplasms because the estimate does 
not reflect that neoplasms account for a higher 
proportion of all hospital visits than of total vis­
‘The National Disease and Therapeutic Index is a 
product of Medical Business Services, a division of IMS 
America, Ltd., Ambler, Pennsylvania. 
its, or that hospital visits are somewhat more 
expensive than office visits. ALso, the proportion 
of short-term hospital surgery discharges with a 
diagnosis classified as neoplasms is significantly 
higher than the proportion of physician visits re- . 
ported for neoplasms. Equal weighting of the , 
cost of hospital versus office visits and of the’ ie-. . 
lative shares among diagnoses of surgic~’wd” “” 
nonsurgical expenditures results in ‘%n under-” 
estimate of expenditures for physicians’ services .’ 
... .related to neopk.sms. 
For this report, expenditures for physicims’. ” 
services have been estimated by the following .,, 
method. Total expenditures for physicians’ serv- ­
ices in calendar year 19756 I were sep”krated 
into those resulting from inhospital surgery ahd ‘ 
other expenditure’s. The proportions used were ‘ 
those observed for the year 1970 in a sukey of 
utilization and expenditures conducted by the 
Center for Health Administration Studies at the 
University of Chicago and the National Opinion 
Research Center$z This survey found that 24 ‘ 
percent of expenditures were for surgery in the 
hospital. 
Next, nonsurgery expenditures for all dis­
eases were split into those for inpatient medical 
care and those for office and other types of vis­
its, taking into account botli the rm”mber of 
visits and differences in average fees for each 
type.63 Total expenditures ,for each place of 
visit were then distributed among cancer sites 
according to proportion of visits reported f,or 
each site. Finally, expenditures for inhospital 
surgery were allocated by site according to tie 
proportion of all short-stay hospital discharges 
with surgery reported for each site by the Hospi­
tal Discharge Survey of the National Center for 
Health Statistics. This assumes equal charges for 
inhospital surgery for every site and probably 
introduces some bias to the allocation of expen­
ditures for surgery among sites. 
By this method, the cost of physicians’ serv. 
ices for neoplasms was estimated at $1.25 biIlion 
(table 14), a cost 85 percent and $574 mil~on, 
higher than the figure in table 1. Ten percent of 
the increase ($60 million) is due to using calen: 
dar 1975 rather than fiscal 1975 expenditures; 3 
percent ($18 million) results from introducing 
the place and relative cost of visits; and 87 per-
cent ($497 million) occurs because expenditures 
. . 
. . .. . .,’s5 
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for surgery were distributed according to the 
number of hospital discharges with surgery as 
opposed to the number of physicians’ visits. 
It is I.ikely that even this revised estimate 
understates expenditures for neoplasms-related 
physicians’ services because the amount of sur­
gery performed since 1970 has increased more 
‘. ,
. ., 
than the number of physician visits. Between 
.’ 
,. 1971 and 1975, there was a 5.7-percent increase 
-., in physician visits and a 22-percent increase in . . . 
.“ the number of short-stay hospital discharges 
with surgery.64-67 Consequently, expenditures 
.,. for surgery probably account for more than one­
. . quarter of all expenditures for physicians’ serv­
ices in 1975, so the share of expenditures allo­
cated to neoplasms, which is surgery-intensive 
compared with all other diseases, is under­
. . estimated. Neoplasms lose 8 cents for every. 
,. dolkr of expenditures in 1975 that has incor­
.,	 rectly been attributed to nonsurgical visits be-
cause the revised estimating procedure awards 
,. 11 percent of surgical and 3 percent of nonsurgi­
cal expenditures to neoplasms. It is unfortunate 
that an up-to-date figure for the distribution of 
expenditures for surgery and nonsurgery visits is 
not available. 
Further considerations, –Other aspects of 
the methodology for estimating direct costs 
should be pointed out. The existence of multiple 
diseases causes some difficulty in distributing 
expenditures by diagnosis. Hospital days, for ex-
ample, are aUocated according to the primary 
diagnosis, but other accompanying conditions 
influence the length and cost of hospital stays. 
The bias introduced by assigning the total cost 
of a hospital episode to the illness indicated by 
the first-listed diagnosis, when a portion of the 
. cost is due to the presence of other conditions, 
has not yet been investigated. 
Furthermore, the methodology does not ac­
count for all economic costs incurred because of 
cancer. Excluded are transportation costs of per-
sons receiving care and visiting patients; costs of 
extra household help for the patient and the 
family; expenditures for retraining or reeduca­
tion, special diets, and special housing facilities; 
free or reduced fee care provided as charity by 
hospitals and other institutions, physicians, the 
family, and friends; subsidies provided to cancer 
patients in the form of fixed hospital rates, with 
less ill patients sharing costs of those mor: ill 
who use more nursing time and ancillary : erv­
ices; free care provided by institutions and nled­
ical personnel as pat of their teaching or 
research function; and losses in the forrr, of 
reduced capital gains due to forced sale of awets. 
Inclusion of these costs would provide more 
complete estimates of cancer costs, but at the 
present time their magnitude is unknown. A re-
cent study estimated some of the non-hea.lth­
sector costs that can be identified. Although not 
a complete evaluation, it found that non-health-
sector costs add at least 12 percent to the total 
cost of all illnesses.68 Unfortunately, costs were 
not estimated by disease category, and it is not 
known what proportion of non-health-sector 
costs is due to neoplasms. 
Finally, some extensions of the usual treat­
ment of direct economic costs, which could pro-
vide additional insight into disease costs, am as 
follows: (a) costs distributed by stage or exl ent 
of disease at initiai diagnosis (e.g., Iocalizecl or 
not), by method of treatment (e g., surgery, ra­
diotherapy, and chemotherapy), or by provider 
characteristics, such as physician’s experienc: in 
treating cancer, available hospital services, and 
whether the institution specializes in cancer 
care; (b) costs distributed over diagnosis, tr:at­
ment, and rehabilitation; (c) costs arising from 
disease complications and treatment side effects; 
(d) costs per person with cancer, including life-
time costs of the disease. Estimates of ti ese 
omissions and extensions have not yet appeared 
in the literature, and at least some of the re­
quired data have not been readily available. 
However, a study investigating some of these 
aspects of direct costs is now underway in the 
United States.6g 
Indirect Costs 
Indirect economic costs result from morhid­
ity and mortality. Morbidit y losses are estimated 
separately for those who are currently rm­
ployed, housekeepers, persons unable to work 
because of ill health, and the institutionalii:ed 
population. Days lost from work among the 
currently employed are converted to years lost 
by age and sex and multiplied by age and sex-
specific estimates of average annual earnings to 
36 
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obtain lost earnings for this group. Days of bed-
disability -suffered by women who usually keep 
h6~se are also converted to years and multiplied 
by age-specific values of housewives’ services to 
ob@in morbidity costs for this group. The num­
ber of persons unable to work by age and sex is 
multiplied by employment rates and average an­
nual eaxnings and by housekeeping rates and 
“housekeeping values to determine indirect mor­
bidity costs among members of this group. A 
similar procedure is applied to the institution­
alized population to estimate morbidky costs by 
institution. These separate components of mor­
bidity costs are aggregated to obtain a total cost 
figure. 
Mortality costs by cancer site.–To obtain 
indirect costs of mortality by cancer site, the 
numbers of deaths for each site in 1975 by age 
and sex are multiplied by the present value of 
lifetime earnings, also by age and sex. The num­
ber of person-years lost due to premature mor­
tality is the product of number of deaths and 
life expectancy at the midyear of the age group. 
This method accounts for life expectancy, labor 
den, discounted to 1975, resulting from the 
prevd,ence of disease in 1975. Included are costs 
of resources used during the year for prevention, 
diagnosis, and treatment; output lost during the 
year because of morbidity; and output lost due 
to deaths in 1975. Because a death in 1975 
means lost output in future years, the present 
discounted value of the future losses is also 
counted. 
It is important to note that, unlike the esti­
mates for mortality, those for morbidity do not 
include the present discounted value of future 
losses resulting from disease in 1975 that may 
cause decreased productivity and lost earnings in 
future years. Other effects of disease besides 
death may decrease future output–for example, 
the lost output of a professional singer after a 
laryngectomy. This decreased output should be 
included in cost estimates. Unfortunately, the 
data for this component are lacking, and the ex-
tent of the underestimate because of its omis­
sion is not known. It must be emphasized that 
the omission is the present cost of future losses 
resulting from morbidity in 1975, and not the 
p~esent cost of future morbidity that may arise 
from disease that has its onset in 1975. The lat­
ter is not relevant to the cost measures in this re-
port, but it is important in the context of the 
cost of disease from onset until cure or death. 
In ad@tion to the costs associated with the 
prevalence of disease in 1975, one might be in­
terested in the cost of disease from onset until 
cure or death. This requires knowing the inci­
dence of disease in 1975 and the likely course of 
the disease, including treatments required, mor­
bidity, and mortality. For any new case in 1975, 
both direct and indirect costs may occur in 1975 
and subsequent years. Because of illness begin­
ning in 1975, a person may require treatment 
for a number of years, lose time from work dur­
ing this period, and eventually die of the disease. 
The total cost is the sum of the present dis­
counted values of all direct costs and earnings 
lost because of morbidity and death. This value 
is the best measure of the savings,or benefits, of 
preventing a new case of the disease. 
A third cost that may be of interest is the 
economic burden of disease that is actually 
borne in’ 1975. This consists of direct costs in 
1975, indirect costs of morbidity and mortaIity 
* 
,. 
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force participation and housekeeping rates, earn­
ings and imputed values of housekeeping serv­
ices, and discount rate for each age and sex 
group. Estimates for 1975 include imputed 
housekeeping values for women and men in the 
labor force who have household responsibilities 
in the present value of future earnings. 
For these calculations, present values of life-
time earnings were those developed by Sehna 
Mushkin at the Public Services Laboratory, 
Georgetown University,28 and mortality data 
were provided by the Division of Vhl Statistics, 
National Center for Health Statistics (NCHS). 
Two different life tables are employed in this re-
port. All lifetime earnings data and estimated 
erson-years lost in table 3 are based on modi­
ed generation life tables developed at the Public 
k rvicr: Laboratory at Georgetown University. 
Person-years lost by cancer site in table 11 are 
based on a current life table for 1975 provided 
by the Division of Vital Statistics, NCHS. A full 
expli ation of the methodology and data used 
to >mpute indirect cost can found 
else~/here .28930 
14emures of indirect costs.–Thi t method­
ology provides an estimate of the economic bur-
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incurred in 1975, and the value of output lost in whether death is related to the disease bein~ 
1975 because of morbidity and mortality in pre- studied, and the impact of disability and detit~ 
vious years, but excludes present discounted on earnings. The third cost measure is rarely esti 
values of future losses of earnings due to mor- mated, but was calculated for cardiovascular dis. 
. bidity ‘and mortality in 1975. eases and cancer in 1962.7° 
,. ~acli of these three measures of costs of dis­
,.- gtie provides different information, and which 
, ‘. ““ ‘one.is most appropriate depends on the question EconomicCostsof Cancerby
.’ being asked. Usually, the cost of disease preva- Site in 1977. ., ,. lenc~ ‘is’“estimated. The cost of disease incidence,. 
-,, ,< is’. more difficult to estimate, requiring projec- Tables I-X present data relating to economic 
“$ tioqs.:bf ireatment and disability over the course costs of cancer by site for hospital care, pllysi­
,, ,of.:the disease. time between onset and death, cians’ services, and mortality in 1977. 
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,,- . . .. Table 1. . Days of care for patients with neoplasms discharged from short-slay hospitals, by cancer site, sex, and age: United States, 
., 
. . celendar year 1977 
,’. 
.’. 
,.
. 
. . . . 
. .
. 
.!’
. . 
,. ..’ Site 
.’ . 
,,. ‘eta’lm­
. 
. . . ‘.,,”’ 
. .’ :.. . . >’,. :, . 
Days of care in short-stay hospitals in thousands 
i, . . . . . 
. . .
.\ 
. . .’
‘.
.,.,..:. 
All neoplasms............................................................................ 25,8~ 9.6 10,750.5 ! 15,069.0 14,001.1 11,316.5 
., 
,. “, J Malignant neoplasms....................................................................... 21.011.8 9,748.8 11,263.0 10,113.7 10,398,1 
.. . . . . 
.— 
, :.’ 
,. @sccal&vity and pharynx ........................................................................ 490.5 332.2 158.3 261.4 229.2 
Stomach ..::............ ................................................................z .................. 460.3 235.6 224.7 195.5 264.8 
,, 
., ]ntestine-and rectum ................................................................................. 
Other digestive organs ............................................................................... 
2,870.3 
872.6 
1,322.3 
459,6 
1,548.0 
412.9 
1,012.5 
320.8 
1,357.7 
551.8 
Trachaa, lung, and bronchus...................................................................... 2,464.7 1,713.9 750.8 1,235.8 1,228,9 
,. 
,’ 
. . “Other resp’iratoryorgens............................................................................ 304.5 246.1 58.4 147.5 156.9 
.
. 
. . 
560.2 288.4 261.9 286.3 264.0 
Breest ........................................................................................................ 2,456.5 43.8 2,412.7 1,393.4 1,,)63.1 
Cewix uteri ..................................................................... ......................... 620.1 . . . 620.1 493,7 126.4 
Other parts of uterus ................................................................................. 497.3 . . . 497.3 237.3 260.0 
Other female genital organs....................................................................... 714.2 ,.. 714.2 374.1 340.0 
Male genital organs.................................................................................... 1.299.4 1,299.4 ,.. 374.7 924.7 
Urirlary organs........................................................................................... 
Other and unspecified sites........................................................................ 
1,349.8 
3,921.9 
877.0 
1,872.3 
472.8 
2,049.6 
536.8 
2,010.2 
312.9 
1:]11.7 
Leukemia .................................................................................................. 615.5 317.8 297.6 379,9 :~35.6 
Other lymphatic and hematopoietic tissues............................................... 1,524.3 740.3 784.0 853,8 070.5 
Benign neoplasms and neoplasms of unspecified nature ................. 4,807.8 1,001.8 3,806.0 3,887.5 !120.3 
., 
. NOTE: Numbers may not add to totals due to rounding. 
SOURCE: Hospital Discharge Survey, National Center for Health Statistics. 
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Table 11. Estimated hospital expenditures for patients with neoplasms discharged from short-stay hospitals, by cancer site, sax, and age: 
United States, calendar year 1977 
Site 
Expenditures for short-stay hospitals in millions \ 
AH neoplasms’ ..... ... .. .... .. .... ...... .... ...... ...... ..... .. .. ...... ...... .... .... ..... $5,768.1 II $2,470.7 $3,297.4 $3,322.1 $2,446.0 
Malignant neoplasms .... ..... ... .. ....... .... ...... .... ..... .. ..... ..... ..... ... ... .... .... 4,618.7 II 2,220.5 2,398.2 2,375.1 2,243.6 
Buccel cavity and pharynx ....... ...... ..... ... . ..... ..... ..... ..... .. .... ...... .... .. .. .. ... .. .. 112.5 77.2 35.4 62.7 49.8 
106.2 57.4 48.7 47.3 56.9 
Intastine and rectum .... .. ..... ...... ..... .... .. .... ... ....... ...... ..... ... ....... ..... .. ... ..... ... 653.9 311.5 342.4 241.8 412.1 
Other digastive organs .. ....... .... ... .. ... .... ... .. ..... ... ... ... .. ..... .. .... ..... ..... .... .... .... 195.9 107.7 88.1 76.7 119.1 
Trachea, lung, and bronchus ... ......... .... ...... .. .. ...... .. .. .. ..... ... ........ .... .. . ..... .... 557.2 388.8 168.4 295.0 262.1 
Other respiratory organs ...... ... .. ...... ...... .... ..... ..... ... ....... ... ... .... ....... .. .. .... .... 75.6 61.6 14.0 38.0 37.6 
SMn ... .... ..... ..... ... .. ..... ..... ..... ...... ...... ..... .... ..... ........ ... .. .... ... .. ..... ...... ... ... .. ... 125.5 69.5 56.0 73.0 52.5 
Breast .. ... ..... .... ...... ..... ..... ..... ..... .. .... ..... ..... ... ........ ...... ... ....... .... .. .. .. .. .. ..... .. 479.6 9.4 470.1 278.6 201.0 
Cervix uteri ...... .... ...... ..... ..... ....... .. .. .... ... ... ....... ... ....... ..... .... .... ........ ... .. ... ., 142.8 . . . 142.8 118.6 24.3 
Other parts of utarus .. ...... .... .. ...... .... .. ... ..... ...... .... ...... ..... ...... .... ...... ..... ... .. 111.9 ,.. 111.9 58.0 53.9 
Other female genital organs ... ..... .... . ... ... ..... .... ...... ...... .... .. .... ...... ..... ..... ..... 158.0 . . . 158.0 91.5 66.5 
Male genitel organs .. .... ..... ...... ...... .... ..... ... ... ..... ..... ... .... .... ...... ...... ... ...... .... 256.8 256.8 . . . 81.6 175.1 
Urinary organs ... ...... ...... ..... ..... ..... .. .. .. .. .. ...... ...... ... ..... ..... ..... ...... ..... ..... ..... 304.1 201.9 102.2 130.8 173.3 
Other and unspecified sites ...... .... ... ..... .... ..... ..... .. .... .... .... ...... ..... .. .... .... ..... 819.5 407.0 412.5 451.3 368.2 
Leukamia .... ... ..... .... ..... ..... ..... ....... ..... ..... .. .... ..... .... .. ... ....... ... ...... .... ...... .... 164.2 90.4 73.8 111.4 52.8 
Other lymphatic and hematopoietic tissues . .. .. ... .... .. ... ........ ..... .... ... ....... ... 355.1 181.4 173.7 218.7 136.4 
Benign neoplasms and neoplasms of unspecified nature ..... .. .. .. .. .. ... 1,149.4 250.2 899.2 947.0 202.4 
NOTE: Numbers may not add to totals due to rounding. 
SOURCES: Expenditures are estimated by the product of days of care, from the Hospital Discharge Survey of the National Center 
for Health S$atietics, and average per diem charges. Clsarges are estimated using average per diem charges to Medicare patients from the 
Health Care Fhrancimz Administration and averarre &ilY hoassital uayments
. . 
from the Third National Cancer Survey of the National
-. . 
Cancer Institute. -
Tebla II 1, Estimatad expenditures for and percent distribution of physicians’ sewices due to naoplasms by cancer site, according to type 
of visit United States, calendar year 1977 
Type of visit 
Site Office Inpatient hospital Office hspatiant hospital Office Inpatient hospital 
,, Total and Total and Total and 
otherl Medical Surgical otherl Medical Surgical otherl Medieal Surgical 
Expenditures in millions Percent distribution by site Percent dktritition by type of visit 
All neoplasm . . .. . .. . . .. .. . . $1,560.7 $374.9 $343.4 $842.4 \ 100.0 100.0 100.0 100.0 100.0 24.0 22.0 I 54.0 
Digestive organs ... . .. . .. . .. . .. .. . .. . .. . .. . 143.0 17.5 45.4 60.1 9.2 4.7 13.2 9.5 100.0 12.3 31.7 56.0 
Respiratory organs .. . .. .. . .. . .. . ... . .. . .. 97.7 12.5 32.0 53.1 6.3 3.4 9.3 6.3 100.0 12.9 32.7 54.4 
Skin . ... . .. .. . . .. .. .. . .. . .. .. . . .. . .. . .. .. .. ... . .. 57.8 24.3 3.1 30.3 3.7 6.5 0.9 3.6 100.0 42.1 5.4 52.5 
Breast...,..,., .. .. .. . .. . . .. .. . .. . .. . . .. .. . .. .. . . 105.6 19.3 22.3 64.0 6.8 5.1 6.5 7.6 100.0 18.3 21.1 60.6 
Female genital organs .. .. .. .. . .. . .. .. .. . 92.6 10.0 11.0 71.5 5.9 2,7 3.2 8.5 100.0 10.8 11.9 77.3 
Male genital organs .. .. . ... . . .. .. . . ... . .. . 64.2 12.8 18.5 32.8 4.1 3.4 5.4 3.9 100.0 19.9 2S.9 51.2 
Leukemia .. .. .. . . .. .. .. . . .. .. .. . .. . .. .. . .. .. . . 28.9 10.8 12,4 ‘6.8 1.9 2.9 3.6 0.8 100.0 36.0 41.4 22.6 
All other malignant neoplasm . ... . 324.7 62.7 122.2 139.8 20.8 16.7 35.6 16.6 100.0 19.3 37.6 43.1 
Banign neoplasms and neoplasms 
of unswcif ied sites .. . ... . .. . .. . .. . .. . . nm 645.2 204.7 76.6 363.9 41.3L 54.8 22.3 43.2 100.0 31.7 11.9 58.4 
10ther includes home, teiephone, nursing home, and other. 
NOTE: Numbers and percents may not add to totsls due to roundins. 
SOURCES: Health Care Financing Administration for total expenditures for physicians’ services; National D~ease Therapeutic Index for physicians’ visits by 
site; James R. Cantwell, cd.: Profiles of Medical Pnrcrice, American Medical Association, Chicago, for average fees; and Hospital Discharge Survey, National Center 
for Health Statisdc.s, for number of short-stay hospital discharges with sursery by site. 
,,
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Table IV. Number of deaths from neoplasms, by cancer site, sex, and age: United Statas, calendar year 1977 
130th sexes Male Female 
— 
Site All Under 45+4 65 years All Under 45.64 65 years All Under 4W4 65 years 
agesl 45 years years and over agesl 45 years years and over ages1 45 years years and ever 
All neoplasms .. . .. .. .. . .. .. . .. . 391.6 22.7 133.9 235.0 212.8 11.2 72.3 11.6 61.7 105.7 
— — —.
- - - —. 
Malignent neoplasms . . .. .. .. . .. . . I 386.7 21.9 132.5 232.2 210.5 10.8 71.6 11.1 60,9 104.2 
—— 
Buccal cavity and pharynx . ... . . ... . .. .. . S.5 0.3 3.9 ~ 4.3 5.9 0.2 2.8 2.9 2.5 0.1 1.1 
Stomach _ . ...— . . .. ...m... . .. .. ... . . .. . 14.4 0.5 4.0 9.9 8.7 0.3 2.7 5.7 6.8 0.2 1.3 Y2 
Intestine and rectum . .. .. . .. .. .. . .. . .. .. . .. . 52.3 1.4 13.9 36.9 25.3 0.8 7.3 17.2 26.9 0.7 6.6 19.7 
Other digestive organs . .. .. . .. . .. .. . .. .. . .. . 36.2 1.0 12.0 23.2 20.4 0.6 7.6 12.1 15.9 0.4 4.4 11.1 
Trachea, lung, and bronchus . .. .. .. . .. . . 90.5 38.8 49.0 6S.6 28.5 38.3 22.0 10.4 10.7 
Other respirato~ organs .. . .. . .. . ... . . .. .. 4.7 z 2.0 2.6 3.7 : 1.6 2.0 1.0 : 0.4 0.5 
Skin . .. . .. .. .. . . .. .. . .. . . .. . .. .. .. . .. . .. .. . . .. .. . .. .. 5.9 0.9 2.2 2,8 3.5 0.6 1.4 1.5 2.4 0.4 O.B 1.3 
Breast . .. .. .. . ... .. . .. .. . .. . .. . .. . .. . .. .. . .. .. . .. . .. 34.8 2.7 15.3 16.8 0.3 0.1 0.1 0.2 34.5 2.7 15.2 16.6 
Cervix uteri .. .. . .. .. . . .. .. . .. . .. .. . . .. .. . . ... . .. . 6.2 0.8 2.2 2.2 . . . . . . . . . . . . 6.2 0.8 2.2 2.2 
Other parts of utarus . .. . .. . . ... . .. .. . .. . .. . 5.s 0.2 1.8 3.8 . . . . . . . . . . . . 6.8 0.2 1.8 3.8 
Other female genital organs . . .. .. . .. . .. . 11.8 0.6 4.9 8.1 . . . . . . . . . . . . 11.6 0.6 4.9 &1 
Male genital organs .. .. . .. .. . .. .. .. .. .. . .. . .. 21.7 0.6 2.7 18.4 21.7 0.6 2.7 18.4 . . . . . . . . . . . . 
Urinary organs .. . .. . .. . . .. .. .. .. . . .. .. . .. . .. . .. 17.4 0.5 4.7 12.2 11.4 0.3 3.3 7.9 5.9 0,2 1.4 4.3 
Other and unspecified sites .. .. . .. . . ... . . 41.4 4.4 13.9 23.0 21.4 2.5 7.7 11.1 20.0 1.9 6.2 12.0 
Leukemia . .. . .. . .. . .. .. . . .. . .. .. . . ... . . .. .. . .. . .. 16.3 3.0 3.6 S.B 8.6 1.7 2.1 4.7 6.7 1.3 1.4 4.0 
Other lymphatic and hemato-
poietic tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21.1 2.1 6.6 12.4 11.1 1.4 3.7 6.0 10.0 0.8 2.9 6.3 
8enign neoplasms and 
neoplasms of unpacified

nature . . . .. .. . .. . .. . .. .. ... . . .. .. . . .. .. 4.9 0.7 1.4 2.s 2.3 0.4 0.7 1.3 2.6 0.4 0.7 1.6

lTotals include persons of unknown ages. 
NOTE Numbers may not add to totals due to rounding. 
SOURCE Division of Vital Statistics, National Center for Health Statistic.% 
. 
Table V. Person-years lost due to neoplasms, by cancar site, sax, and aga: Unitad States, calendar yaar 1977 
Both sexes Male FerMla 
— 
3ita All under 4s.64 a5 years All Un&r 45.s4 a5 yaars All Under 46e4 66 ymrt 
CQw 46 years years and over cW 45 yearc years I and mar ages 46 years yews and (Iwr 
— 
I Person-years lost in thousands 
All neoplasm . ..... .. ...... ...... .. 2,903.2 2,392.7 3,01S.2 467.2 1,373.9 1,177.1 I 3,270.9 [1 52a.o I 1,528.3 I 1;?16,,5 
kc 
Malignant neoplmnrs . ...... ......... 6,192.3 955.7 2,a71.9 2,364.7 2,97a.o “449.7 1,3ao.7 1,165.7 3,21 &3 505.0 1,511.2 1,189.1 
.— 
aucccl cavity and pharynx . ... ....... ... .... 136.4 12.6 80.0 43.7 90.0 8.5 53.7 27a 46.4 4.2 26.3 16.9 
stomti .. ... ........ .... ....... ....... .......... .. ... 197.3 1s.3 63.5 95.6 111.6 10.2 51.4 EO.o a5.7 32.1 45.6 
Intestine and rectum ..... ........ .......... .... 720.0 55.9 29a.a 367.4 317.a 27,a 137.7 152.3 402.3 2:2 159.1 215.0 
Other digastiva organs .... .......... .. ......... 527.5 
Trachea, lung, and bronchus ..... .......... 1 ,400.a 
38.8 
86.3 
249.7 
799.2 
239.0 
505.0 
279.6 23.2 144a 111.a 
970.1 5a.7 S42.3 371.0 
247.9 
430.5 
15.7 I 
39a I 
105.0 
256.9 
27.2 
‘34.0 
Other recpiratmy organs .. .. ........ ......... 72a 7.1 40.9 24a 53.9 4.B 30.5 la.a 18.7 2.3 10.5 6.9 
Skin ........... ...... ......... ............ ....... ...... . 1 f 4.3 38.0 48.6 27.7 a3.o 21.5 27.6 13.9 51.3 16.5 20.9 13.a 
6reati .............. ............ ......... .. ........ ..... 697.5 110.7 3ss.5 198.3 4.0 0.5 2.1 1.4 693a 110.2 38a.4 ,96.9 
Cewix uteri ..... .. .... ........ ........ ........... ... 115.8 33.6 55.9 2a.3 . . . . . . . . . . . . II 5.a 33a 65.9 2a.3 
Other parts of uterus ..... .. ....... ........... .. 95.3 43a 44.0 . . . . . . . . . . . . 95.3 7.51 43a 44.0 
Othar female gmital organs...... .......... . 220.8 2Z 121.8 73.8 . . . .,. . . . . . . 220.8 25.2 121,8 73<a 
Male genital organs..... ... ........ ..... ......... 222.s 24.4 47.6 150.8 222.8 24.4 47.6 150.8 . . . . . . .,, . . . 
Urinary organs ..... ........ ......... ...... ........ 232.7 20.1 96.0 11 a.6 142.1 10.9 62.o a9.2 90.6 9.2, 34.1 47.4 
Other and unspecified sites .... ........ ..... 753.5 212.8 301.9 23s.a 387.3 115.4 149a 102.3 38a.3 97,4 152.3 3a.6 
tiukemia ............ .. .......... ... ...... ......... .. 319.4 15s.1 76.5 a4.a la9.2 S7.I 41.1 41.1 150.1 71.0 36.5 43.7 
Other lymphatic and hemato-
poietic tissues....... ... ............ ..... ... ..... [1 365.7 9a.2 141.1 ~2a.4 1s4.7 58.9 70.5 55.3 lao.9 37.3 70.4 73.f 
Benign neoplmms mrd 
neopla$nrs of unpacified 
nature ... ............ ... ...... .. ......... . 9a.a 37.5 31.4 27.9 42.2 17.5 13.3 11.4 a4.a 19.9 Ia.1 1e.s 
— 
NOTE: Numbecc may not add to totals due to rounding. 
SOURCE Number of deaths and current life tables for 1977 from the Division of Wal Statistics, National Center for Health Statistics. 
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Table VI. Person-years lost per death due to neoplasms, by cancer site, sex, and age: United States, calendar year 1977 
Both sexes Male Female 
Site 
All Under 45-64 65 years All Under 45-64 65 years All Under 45.65 65 years 
ages 45 years years and over ages 45 years years and over ages 45 years years and cwer 
Person-years lost par death 
, 
. 
, 
‘, 
.,. 
All neoplasms .. .. . .. . .. . . ... . .. . .. .. . 16.1 43.8 
Malignant mroplasms. ... . . .. . .. .. .. .. .. 16.0 43.6 
Buccal cavity and pharynx . .. . .. . .. . ... . .. . .. . . 16.1 3B.9 
Stomach . ... .. . .. . .. . .. . .. . .. . . .. .. . .. .. .. . .. . .. . .. . .. . . 13.7 37.5 
Intestine and rectum . .. . .. . .. . .. .. . .. . .. .. . .. .. . . . 13.8 38.9 
Other digestiva organs .. .. . .. .. . .. . .. .. .. . .. . . .. .. 14,6 39.0 
Trachea, lung, and bronchus .. . .. .. . .. . ... . . .. 15.5 35.7 
Other respiratory organs . .. .. .. . .. . .. .. . .. . .. .. . 15.5 40.4 
Skin . . .. . .. . .. . .. . .. . .. . .. . .. .. .. .. . . .. ... . . . ... . .. .. . .. . .. 19.3 40.7 
Breast .. . .. .. .. . .. . . .. .. . .. . .. . .. .. . . .. .. . .. .. . .. .. . .. . . .. 20.1 40.9 
Carvix uteri . . .. . . .. . .. ...$. . .. . .. . .. .. . .. . .. .. . .. . .. . .. 22.4 42.1 
Other parts of uterus .. . .. .. . .. .. . . . .. .. .. . .. . .. . . 16.5 42.8 
Other female genital organs .. . .. . .. . .. . .. .. .. . 1B.O 43.2 
Mala genital organs . .. . .. . . .. . .. . .. .. . .. . .. .. . .. .. . 10.3 43.8 
Urinary organs . .. .. . .. . .. . . .. . .. . .. . . .. .. . .. .. . .. . . .. 13.4 42.2 
Other and unpacified sites .. . .. . .. . .. . .. . .. .. . 18.2 4B.2 
Leukemia .. .. . .. . .. .. . . .. . .. .. . . .. . .. . . .. .. . .. . .. . .. .. . . 20.8 52.6 
Other lymphatic and hemato-
poietic tissues . .. . .. .. . .. . .. . .. . .. . .. . . .. .. . .. . .. . .. 17.3 45.0 
rr 
Benign neoplasirw and 
neoplasms of unspecified 
nature .. . .. . .. .. . . .. . .. .. .. . .. . .. . .. .. . .. . .. . 19.7 50,2 
21.7 
21.7 
G 
20.7 
21.3 
20.8 
20.6 
20.2 
22.2 
25.4 
25.7 
23.9 
24.B 
17.4 
20.5 
21.7 
21.5 
21.5 
22.3 
10.2 I 14.2 II 41.8 
10.2 14.1 41.8 
10.2 15.2 36.7 
8.6 12.B 34.4 
10.0 12.5 36.2 
10.3 13.7 36.5 
10.3 14.2 33.3 
9.9 14.6 3B.2 
9.9 18.1 3B.2 
11.8 14.1 35.B 
12.0 . . . . . . 
11.7 . . . . . . 
12.1 . . . . . . 
B.2 10.3 43.8 
9.5 12.4 3B.1 
10.4 17.2 45.6 
9.7 19.7 50.1 
10.4 16.7 43.0 
10.1 18.0 [ 46.6 
19.0 9.1 I 18.3 II 45.9 24.8 I 11.5 
19.0 24.8 I 11.5 
19.4 9.5 IB.4 ii 44.3 
18.9 8.B 14.9 II 42.3 
18.7 8.8 14.9 41.9 24.1 10.9 
19.0 9.2 15.6 43.4 24.0 11.4 
19.0 8.7 19.5 39.7 24.8 12.6 
19.0 9.5 19.2 45.B 24.7 11.9 
20.2 9.0 21.0 44.4 25.7 11.0 
19.2 8.8 20.1 40.1 25.4 11.9 
. . . .“-1 42.1 25.7 12.0. . 22.4 
. . .Ill
17.4 B.2 . . . . . . . . . . . . 
18.9 B.B 15.3 46.4 24.1 10.9 
19.3 9.2 19.3 51.7 24:7 11.4 
19.3 8.7 22.4 56.1 24.B 10.9 
19.2 8.2 lB.1 48.7 24.5 11.5 
. . . 16.5 42.B 23.9 11.7 
. . . . . . 19.0 43.2 24.8 12.1 
19.4 8.9 21.1 53.7 25.0 11.1-L --L
SOURCE: Number of deaths and current Iife tables for 1977 from the Division of Vitcf Statistics, National Center for Health Statistics. 
Table VI 1. Present value of lifetime earnings discounted at 6 percent and 10 percent, by sex and age: United States, “calendar year 
1977 
Age 
Under 1 year .. ..... ... .... ..... ..... .. ...... .... ..... .... ..... .... .. ... ...... ... ..... ..... ..... ..... ...... ..... ..... .... ... 
1-4 years ... .... ..... ..... ..... .... ..... ..... ..... .... .... ..... ..... ..... ...... .... ..... .... ....... .... ..... .... .. ..... ..... ... 
5-9 yeara...J .. ..... .. .... .... .... ...... ...... .... ...... ..... ..... ...... ... ... .... ..... ....... ..... ..... ..... ...... .... ... ... .. 
10-14 years .... ..... .. .... ...... ..... ..... ...... ..... ...... ..... ...... ..... ..... ..... ...... ...... ..... ..... ...... ..... ..... .. 
15-19 years ...... ...... ...... ... ...... ..... ..... ....... .... ..... ..... ....... ..... ..... ..... ...... .... ...... ..... ....... .... .. 
20-24 years ...... .. .... ..... ...... .... ..... ...... ...... .... ...... ... .. ..... .... .. ..... .... .. ..... ...... .... ...... .... ....... . 
26-29 yeara . ..... .... ... ..... ..... .... ...... .... ...... .. ... ..... ....... .... ..... ...... ...... ..... .... ..... ....... ..... ..... .. 
30.34 years ...... .... ..... ...... ...... ..... ..... ...... ..... ..... .. .... ..... ..... ...... .. .. ........ ..... ... .. .... ...... ..... .. 
35-39 years ...... ....... .... .... .. .... ..... .. ..... .... ...... ..... ...... .... ...... ..... ...... ..... ..... ..... ..... .... .. ..... .. 
4044 yeare ..... .... ..... .... .. .... .... ..... ....... ... ...... ..... ...... .... ...... ..... ...... .... ...... .... .. .... ...... .... ... 
45-49 years ..... ..... .. .. .. ... ....... .... ... .. ... ... ... ... .. ...... ..... ..... .... ....... ... ....... ..... .... .... ........ ..... .. 
50-54 years .... .... ...... .... .... .. .... ...... .. .. ... .. ..... ...... ..... ..... ...... ...... .... ...... ...... .... ..... ..... ... .. ... 
55.59 yeare.o .. ... .. ..... ..... ... .. ... .. ...... ... ... ... ..... .... .. .... ...... ..... ..... ...... ..... ..... ...... .... ...... .... .. . 
60.64 years ....... ..... .... ..... ....... ..... ..... .... ....... .... ...... .. ... ..... ...... ..... ...... ..... ...... ..... ..... ...... . 
65-69 years .... .... .. .... ....... ... ..... ... .. .. .... ..... ... ... .... ..... ...... ....... .... ...... ... ....... ....... .... .... ..... . 
70-74 yeara .. .... ...... ..... ...... .... ..... ..... ...... .... .... .. .. ... ..... .... ....... ...... ... ...... ...... ..... ...... ... .. .. . 
75.79 years ..... ....... ..... .... ...... ..... .... ...... ...... ..... ... ......... ... ...... ... .. ...... ...... .. .. ... .. ...... .... .... 
80-S4 years ..... ..... ..... .... ..... ..... ..... ........ ... .... ...... ..... ..... ...... ...... ... ...... ..... ..... ..... ...... ..... .. 
85 yews and owrr .. .. ..... ... ... .... .... ..... .... ....... ... ... .... ... .. .. .... ..... .... .... ... ..... ..... ..... ....... .... .. 
Present value of lifetime earnings 
6-percent discount I 1O-percent discount 
Mala I Famaie I Male Famale 
$156,162 $125,805 $43,621 $38,161 
172,559 138,911 52,879 46,224 
205,657 165,449 74,452 65,041 
249,731 200,775 108,802 94,988 
297,371 233,629 152,448 128,201 
334,607 247,995 193,287 148,820 
348,597 240,432 218,615 151,167 
337,837 221,321 225,129 143,156 
307,183 199,812 215,071 133,116 
264,928 176,640 194,195 121,533 
216,456 151,776 166,537 107,929 
162,995 125,961 131,699 92,658 
106,218 99,109 89,865 75,127 
53,834 73,306 46,749 56,754 
22,741 52,651 19,542 41,519 
11,621 37,908 10,123 30,731 
5,967 27,097 5,270 22,713 
3,213 19,708 2,897 17,352 
1,000 6,049 955 5,775 
NOTE: An increase in productivity of 2 percent a year is projected in these calculations. 
SOURCE: Division of Analysis, National Center for Health Statistics. 
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Table VI Il. Present discounted value of lost eernings due to neoplasms at 6-percent discount rate, by cancer site, sex, and ag! 
United States, celendar year 1977 
Both sexes ‘ Mda FMMl, 
aim All Under 45.64 a5 W= All Undar 4E44 a5 vows All Un&r 46-54 )Ia yotrs 
*5 45 yews yews and over ages 45 years years and ow ages 45 Vem wars .nd owr 
u 
I Lest wminpt in millions 
. ... .... . .. 424,297.0 $5,510.3 $14,104.6 34.562.6 s12.4ix3.e - awa.a a7.7e5.3 swa.e w l,a7a.5 ‘ a2,271.a 46,32s.41 a2,26a, 
. ydm nuQ18xIn . ...... . . 22,803.8 5,222.4 13,s52.0 4,a2a.9 12,225.1 3,122.4 7Aaa.o wx.e 1l,aaa.o 2.185.7 ls,2a4.o 3,222, 
S.usml sn’ity md plwynx. . ...... . . . 5S5.6 6s.1 421.2 7s.3 416.7 66.5 312.9 36.2 1ea.9 ls.a 105.2 “ 43. 
.. .. .. ... . .... ..... . .... ... . 7~7.e 124.6 419.2 173.7 431.0 66.6 267.3 57.2 266.6 35.0 131,9 116, 
. . ,. Inmstim WS wtum . . . . . ....... . 2,501.7 358.0 1,408.1 733.6 1,161.8 225.8 7s.6 175.4 1,240.0 132.2 640.6 am. 
Otfmr dk=wa Plums . . . . . . . . . . . . . . . 1,s719 2aq4 1,242.8 47e.a I, R32.4 160.7 e14.9 137.6 826.6 59.6 427.9 341. 
TruilN, Iulw, �nd bronchus. .... . 5,!siz.5 aea.z 4,137.3 656.1 4,041.4 482.2 3,072.3 4ae.e 1,6s1.1 1563 1,0s6.0 3m. 
Otfmr MPirmoly . . .. . . . . . .. .. .. 03.6 1 46.1 216.a sa.a 223a 37.7 172.2 22a 10.4 43.3 16, 
All noaplaxna.
Or!mu Skin------..-.--.....-..-...1 %,, 2,50.0 3WL4 I 73a 170.2 1a.5 2%: 7a.4 6a,4 3a. 
e- . . ... ... . . . . . . .. ....... ... . 627.3 1m?; %5 17.3 3.7 12.0 1.6 2,565.0 523.6 1,623.5 527. 
1!sS.3 226.o 72.8 . . . ... . . . . . . 456.1 16s.3 226.0 72.IMvixutwi.......... ...... . ................. I 2X%11

OtherPwt3 of utma . . ...... ....... ..... 322.7 35.1 177.9 lle.7 . . . ... I . . . . . . 332.7 35.1 177.9 119,
. 
. . .0sh9rtimde gmitd mum. .. ....... e26.f 1le.3 aoa.e 204.3 . . . la.3 S05.6 204. 
Mdc wnital orgsnt. . ......................... 556.4 ve.e 228.2 I eo.e I 556.4 I mblj 2i8i] ,+j;l 8:’.II “::1 -::1 . . . 
~~~*r~n~u”**ifl~ sites............l 3,~11 1~~1 l~d;l WI 1,712.8 71 e.o xl 1~1 1,371.1 %1 RI % 
Lwbmh . .................. ...................... I,a 738.6 264.6 . 
Otlmr Iwnphstic �nd hwnsta-
. . ............................ l,53e,6 578.5 6s5.0 265.o 667.3 415,4 404.7 67.2 651.2 163.1 2s0,3 197. 
Urinary 0rgcn9................................. 
~11 ~11 
Pdotk tfssum.
6mbn IWW4asmsand 
rmwkatns of unspecifkd 
nstum . ............................... 267.2 177.9 152.6 56.7 195.7 105.2 77.3 13.3 lel.5 72a 78.4 43. 
Table IX. Present discounted value of lost earnings due to neoplasms at 10-percent discount rate, by cancar site, sex, and agn 
United States, calendar year 1977 
6oth S9XSS Mala Fwnsk 
Siw All Undw 46.54 65 years All Un&r 45-s4 66 yaws All Un*r 4E-54 t5 yaws 
WS 4a wars ymms �d owr Ws 45 years Wars �nd OvOr *S 45 ymrs V,*IS and owr 
I II 
‘All MOPkan$ .................. $la,543.1 33,506.4 I $11,129.4 I 43,905.21 3S,6S3.3 It 32,064.9 I 3S,394.2 I $1,230.1 I 46,853.9 $1 ,443a I 44,736.3 I $2,67a. 
Malignant nmpkmw . ... ....... 
-+ 1,401.3 I 
euccd cavity and phwnx ............... 333.5 45.3 25a.~ 31.4 128.2 12.0 all 35. 
stOrMch ........................................... 247.4 236.9 49.7 220.3 25.2 98.7 
Intcttlm and rectum ...................... .. 936.e l% a27.7 152.4 I ,025.a e7sf 467.6 4% 
Other digmtiva orgsn$.................. 915.1 123.7 671.8 119.6 64s.5 45.4 321.4 279. 
Trachea, lung, and bronchus............ 3,2s5.1 243.5 2.528.7 421.9 1,22s.2 126.1 795.7 307. 
Otlw retplrstow organs.................. 187.e 25.2 141.s 20.6 52.1 6.a 32.4 
Skin ............... .................................. 26e.o 1I e.4 126.: 14.3 144.5 49.6 a5.6 E 
emaa ........................ ...................... 13.8 2.6 e.s 1.4 waa.e 350.5 1,207.a 43a, 
(%vix utnri ...................................... . . . . . . . . . . . 340.3 lo5.a 176.3 5a. 
Other parts of uterus ....................... . . . 264.7 23.1 133.7 97. 
377.6 
7a,27i.2 3,403.2 11,ooe.e 3,e5a.o 9,551 .a 2,002.0 e,330.9 1,21 a.6 6,719.7 1 - 4,a79.1 I 2,a39, 
Otlw fmwk genital owns. . ............ 620.1 76.1 16s.4 . . . ezo.1 76.1 1ss.

Msk gmital organ:........................... 425.5 112.0 192.0 131.4 131.4 . . . ,.. .. .

Urinary orgmw................................. e3a.8 75.9 391.2 w.a 66.3 228.0 22.3 104.4 101:

other and unmscificd sites.............. 2,24e.7 657.3 1.162.8 406.5 108.6 883.7 223a 471.2 2Q6.

304.5 
Oslmr lymp4mticand hwrmto-
p.aktlc tinucs ................................ 1,132.7 362.6 549.7 220.6 e51.3 zao.e 332.4 58.3 4al.4 102.0 217.3 162. 
~nign nwolmms nnd 
nscfslmrmof unwified 
rmrum................................. 271.9 loa.2 119.5 47.2 137.7 62.9 62.3 11.5 124.2 42.3 E4L2 3a. 
Lmk9mk.. ....................................... a51.5 414.2 
377.6 
II132.6 36.7 346.2 146.4 109.6 93

NOTE Nu;ber$ msy not add to totals due to rounding. 
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Table X. Estimated amount and percent distribution of expenditures for short-stay hospital care and physicians’ services due to 
neoriasms and indirect costs of mortality at 6- and 10-percent discount ratas, by cancar site: United States, calendar yaar 1977 
Indirect costs ofExpenditures for: 
mortality 
Site [ Short-stay Physicians’ 6-percent 1O-percent
hospital 
services discount discount 
care 
Amount in millions 
All neoplasms .. .... .... .. .... .... ..... .... .. ... .. .... .... ...... ...... ... ..... ... ... ... .... ..... .... $5,768.1 $+,560.7 $24,297.0 $18,543.1 
.’ 
Digestive organs ..... ........ .. ... .... ....... ...... ..... ..... .. ... ..... .... ... ...... ... .. .... ... .. .... .... .... .... 956.0 143.0 5,191.2 4,100.9 
. ., 
Respiratory organs .... ..... ..... .. .... ...... .. ....... ..... .... .... ...... .... .... ..... ... .. ..... .... .... ..... .... 632.8 97.7 5,976.0 4.764.0 
,; Skin .. ...... ...... .... .... ... .... .... ..... ..... .... ...... ..... .. ...... ...... ... .... ..... ..... ..... .... .... .... ..... .. ... 125.5 57.8 560.8 413.5 
Breast .. ....... ... .... .... .. .. ...... .... .. .... .. .. ..... .... ..... ... ...... .. ... ..... .... ... ...... .. ... ..... .... ... ..... .. 479.6 105.6 2,702.3 2,010.7 
Female genital organs . .. ... ....... ... ..... .. ... ...... ..... ...... .. ........ ... ..... .... ..... ... .. ... ..... .... ... 412.7 92.6 1,626.9 1,215.1 
Male ganital organs .. .. .... .. . ..... ...... ...... .... ..... ..... ... ...... .... ... ...... ... ...... .... .... .... ..... .... 256.8 64.2 558.4 “435.5 
Leukemia . ....... .... .. ... ... .. ..... ... ..... ..... .... ... .... .... ... ...... ... .. ... .... ..... ...... ... .... .... ...... .... 164.2 29.9 1,261.5 651.5 
All other malignant neoplasms .. ..... ... ..... ..... .. .... .... ..... .... .... .... .... ....... ... ...... .. .. ..... 1,591.2 324.7 6,012.7 4,480.0 
Benign and unspecified neoplasms .... ..... .... ..... ...... .... .. .. ... .. .... ..... .... .... .. .... ...... ... . 1,149.4 645.2 387.2 271.9 
Percent distribution 
All neoplasms ..... ...... ... .. ... ..... ... .. ..... ..... ..... ..... ..... ... ..... .... ..... ...... .... ..... 100.0 100.0 100.0 I 100.0 
Digestive organs ....... ..... ..... ..... .... ...... ..... .... ..... ..... ... .... .. .... ..... .... ... .. ... ..... .... .. .. . ... 16.6 9.2 21.4 22.1 
Respiratory organs .... .... ... ..... ..... ...... ...... ... ..... ...... ..... .. .. .... .... .... .. .... .... ...... ...... ... . 11.0 6.3 24.6 25.7 
Skin .. .... .. .. ..... ..... .... .. .. .. .... ..... ...... .... ...... .... ... .. ..... ... ...... .... .... .... .... .. ..... ...... .. ....... 2.2 3.7 2.3 2.2 
Breast .. .. .... ..... ... ...... .. ..... .. .. .... ..... .. .... .... ..... .... ..... .. ... ... ... .... ... ..... ... .. .... ...... ... .. .. ... 8.3 6.8 11.1 10.8 
Female genital organs ... ..... ..... .... .... ........ .... .... .. .. ..... ... ...... ..... .... .... ...... .... .... ..... ... 7.2 5.9 6.7 6.6 
Mete genital organs ...... ... ....... ..... ...... ... .. .... .... .... .... ...... .... .... .... .... .. ... ..... ..... ..... .... 4.5 4.1 2.3 2.3 
Leukemia ... ..... .... ... .... ..... ... ......... .... ..... .... .... ..... ...... ... .... ...... ..... .... ... ...... .... ..... .... 2.8 1.9 5.3 4.6 
All other malignant neoplasms .. .. ..... ..... .... .... .... ..... .... ..... ..... .... ... .. .... ..... ... ...... ... . 27.6 20.8 24.7 24.2 
Benign and unspecified neoplasms ....... ...... .. .... .. ... ..... .... .... ... .. ..... .... ...... .... .... .... . 19.9 41.3 1.6 1.5 
NOTE: Numbers and percents may,not add to totals due to rounding. 
000
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Series 2. 
Series 3. 
Series 4. 
VITAL AND HEALTH STATIS”!VCS Swiss 
Progroms and Collection Procedures. —Reports which describe the general pr,~~rims 01 th,~ N,ItIIII,[i 
Center for Heafth Statistics and its offices and divisions and data collection methods LId mid i)t,l,t! 
definitions and other material necessary for understanding the data. 
Data Evaluation and Methods Research. –Studies of new statistical methodology including experi­
mental tests of new survey methods, studies of vital statistics collection methods, new analytical 
techniques, objective evaluations of reliability of collected data, and contributions to statistical theory. 
Analytical Studies. –Reports presenting analytical or interpretive studies based on vital and health 
statistics, carrying the analysis further than the expository types of reports in the other series. 
Documents and Committee Reports. –Firsaf reports of major committees concerned with vital and 
health statistics and documents such as recommended model vital registration laws and revised birth 
and death certificates. 
Series 10.	 Data From the Health Interview Survey. –S tatistics on illness, accidental injuries, disability, use of 
hospital, medical, dental, and other services, and other health-related topics, afl based on data collcctcd 
in a continuing national household interview survey. 
Series 11.	 Data From the Health Examination Survey and the Health and Nutrition Examination Survey. –Dat a 
from direct examination, testing, and measurement of national samples of the civilian noninstitu­
tionalized population provide the basis for two types of reports: (1) estimates of the medically defined 
prevalence of specific diseases in the United States and the distributions of the population with respect 
to physical, physiological, and psychological characteristics and (2) analysis of relationships among the 
various measurements without reference to an explicit finite universe of persons. 
Series 12,	 Data Fro m the Institutionalized Population Surveys. –Discontinued effective 1975. Future reports from 
these surveys will be in Series 13. 
Series 13.	 Data on Health Resources Utilization. -Statistics on the utilization of health manpower and facilities 
providing long-term care, ambulatory care, hospitaf care, and family planning services. 
Series 14.	 Data on Health Resources: Manpower and Facilities. –Statistics on the numbers, geographic distri­
bution, and characteristics of heafth resources including physicians, dentists, nurses, other health 
occupations, hospitals, nursing homes, and outpatient facilities. 
Series 20.	 Data on Mortality. –Various statistics on mortality other than as included in regular annual or monthly 
reports. Speciaf analyses by cause of death, age, and other demographic variables; geographic and time 
series analyses; and statistics on characteristics of deaths not available from the vital records based on 
sample surveys of those records. 
Series 21.	 Data on Natality, Marriage, and Divorce. –Various statistics on natality, marriage, and divorce other 
than as included in regular annual or monthly reports. Special anafyses by demographic variables; 
geographic and time series analyses; studies of fertility; and statistics on characteristics of births nnt 
available from the vital records based on sample surveys of those records. 
Series 22.	 Data From the National ,Jlortality and ,Vatality Surveys. -Discontinued effective 1975. Futurt rep,, rts 
from these sample surveys based on vital records will be included in Sencs 20 and 21, respectively. 
Series 23.	 Data From the National Survey of Family Growth. -Statistics on fertility, family formation and dis­
solution, family planning, and reIated maternal and infant health topics derived from a biennial survey 
of a nationwide probability sample of ever-married women 15-44 years of age. 
For a list of titles of reports published in these series, write to: Scientific and Technical Informatif-,n Branch 
National Center for Health Statistirs
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Hyattsville, kid. 20782

